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SUMMARY 
 
Hereditary nonpolyposis colorectal cancer (HNPCC) is characterized by a dominantly 
inherited predisposition to early onset cancer, mostly colorectal (CRC) and endometrial 
cancers (EC). It accounts for 1–6% of all CRC cases and is the most common form of 
hereditary colon cancer.  
 
HNPCC is associated with a deficiency of mismatch repair (MMR) machinery, which is 
responsible for repairing polymerase errors occurring during DNA replication and re-
combination. As a consequence of replication errors, HNPCC tumor cells show instability in 
their genomes, especially in repetitive sequences such as microsatellites. HNPCC-
predisposing germline mutations have been found in four MMR genes: MLH1, MSH2, 
MSH6, and PMS2. MLH3 and PMS1 have also been linked to HNPCC susceptibility, but 
their roles are less clear. One half of ∼450 mutations reported in an HNPCC mutation 
database affect the MLH1 gene, 39% affect MSH2, and 7% MSH6. So far it is relatively 
unclear whether, and how, the different types of MMR gene mutations cause different 
disease phenotypes. Furthermore, a significant number of mutations, especially in MLH1, are 
of the missense type, whose pathogenicity is difficult to interpret.  
 
Here, the functional significance of 31 nontruncating MLH1 mutations found in clinically 
characterized colorectal cancer families and three other variations listed in a mutation 
database were studied for protein expression/stability, subcellular localization, interaction, 
and repair efficiency. Furthermore, by correlating the genetic and biochemical data with 
clinical data, we aimed to determine genotype-phenotype correlations in the families under 
study and in HNPCC in general.  
 
Twenty out of 34 mutations affected the quantity of the MLH1 protein, whereas only 15 
mainly aminoterminal mutations were defective in an in vitro repair assay. Altogether, 22 
mutations were pathogenic in more than one assay. Two variants were impaired only in one 
assay, and 10 variants acted like the wild type protein in all assays. We found that amino-
terminal MLH1 mutations caused protein instability and defective mismatch repair, whereas 
the pathogenicity of carboxylterminal MLH1 mutations was mainly linked to protein 
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instability. The MLH1 alterations which were pathogenic in several functional assays were 
found in families with typical HNPCC characteristics such as early age of cancer onset and 
high MSI phenotype in tumors. Mutations with no defects in the functional assays are 
associated with variable and mild clinical phenotypes.  
 
Our results show that pathogenic nontruncating alterations in MLH1 may interfere with 
different biochemical mechanisms, but generally more than one. MLH1 alterations with 
multiple, mild, or no defects in functional assays are linked to distinct clinical phenotypes. 
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INTRODUCTION 
 
Hereditary nonpolyposis colorectal cancer (HNPCC) is an autosomal dominantly inherited 
cancer syndrome characterized by an overall penetrance of 80%, cancer diagnosis before the 
age of 50 years, proximal colon cancers as well as extracolonic cancers, namely endometrial, 
gastric, small bowel, hepatobiliary, ureteric, and ovarian (Lynch et al. 1993). On the other 
hand, clustering of the tumors belonging to the HNPCC spectrum is observed in 
approximately 15–25% of all colorectal cancer (CRC) kindreds (Wagner et al. 2003). 
HNPCC accounts for 1–6 % of all CRC cases and is the most common form of hereditary 
colon cancer (Aaltonen et al. 1998). 
 
Mutations linked to HNPCC affect the DNA mismatch repair (MMR) machinery, which is 
responsible for repairing polymerase errors occurring during DNA replication and re-
combination. Cells deficient in MMR display hypermutability of their DNA, which leads to 
clustering of mutations particularly in coding- and noncoding repetitive sequences and, 
finally, to cancer development. As a characteristc of MMR deficiency, HNPCC tumor cells 
show microsatellite instability (MSI) in their genomes (Aaltonen et al. 1994).  
 
Since the mapping of the first susceptibility locus on the chromosome 2p and cloning of the 
MSH2 gene (Fishel et al. 1993; Peltomäki et al. 1993), HNPCC-predisposing germline 
mutations have been found in four MMR genes: MLH1, MSH2, MSH6, and PMS2 (Peltomäki 
and Vasen 2004). In addition, MLH3 and PMS1 have been implicated in prediposition to the 
syndrome, but their roles still need to be examined properly. One half of ∼450 HNPCC-
associated mutations registered in the InSiGHT (International Society for Gastrointestinal 
Hereditary Tumors) database occur in the MLH1 gene, 39% in MSH2, and 7% in MSH6 
(http://www.InSiGHT-group.org/; Peltomäki and Vasen 2004). The associations between 
HNPCC genotypes and phenotypes are poorly understood (Peltomäki et al. 2001). Families 
carrying a mutation either in MLH1 or MSH2 tend to display typical HNPCC, whereas MSH6 
mutations are often associated with atypical HNPCC characteristics, such as small family 
size, excess of extracolonic cancers, late age of onset, and reduced penetrance (Vasen et al. 
2001; Hendriks et al. 2004; Peltomäki and Vasen 2004).  
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Of all mismatch repair gene mutations reported in the InSiGHT database, 29% are of the 
missense type, changing only one amino acid, whereas the majority of the mutations cause 
truncation of the polypeptide (Peltomäki and Vasen 2004). The interpretation of the 
functional significance of the minor nontruncating gene variants is difficult. Theoretically, 
the criteria in support of pathogenicity of a missense alteration include evolutionary 
conservation of the original residue, nonconservative nature of the amino acid change, 
absence of the gene variant in the normal population, and its cosegregation with the disorder. 
Moreover, in HNPCC tumors, pathogenicity is suggested by MSI and lack of the appropriate 
protein. However, the lack of clinical samples or insufficient family size often hinder 
conclusions, and the pathogenicity of a gene variant should be functionally characterized.  
 
The present study was undertaken to evaluate the pathogenicity of 34 MLH1 germline 
alterations, some of which were novel, and some have been reported in the InSiGHT 
database. Our aims were to elucidate whether the minor MLH1 gene variants found in 
suspected HNPCC families are pathogenic and the biochemical mechanism of their 
pathogenicity. Finally, by comparing the biochemical data with clinical data obtained from 
the families we aimed to find genotype-phenotype correlations useful in HNPCC diagnostics, 
counseling and design of appropriate follow-up and treatment strategies for gene variant 
carriers in the respective families as well as in HNPCC in general.  
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REVIEW OF THE LITERATURE 
 
 
Overview of hereditary nonpolyposis colorectal cancer 
 
Colorectal cancer in general 
 
Colorectal cancer (CRC) is the third most common cause of cancer-related death in the 
western world (Nataryan and Roy 2003). It is estimated that 105,500 new colorectal cancers 
occurred in the US in 2003. In Finland, approximately 2,200 new CRC cases are found 
annually (Finnish Cancer Registry, http://www.cancerregistry.fi). The average age at 
diagnosis for colorectal cancer is 70 years, and 55–60% of patients survive beyond five years 
following diagnosis (http://www.cancerregistry.fi).  
  
The development of cancer consists of complex events which may involve many environ-
mental factors in addition to possible genetic predisposition. Lifestyle-related factors such as 
a high-fat/low-fiber diet and long-term smoking are known to be associated with an increased 
risk for colorectal cancer (Potter 1999).  
 
Cancer is the endpoint of a stepwise process which requires a series of different genetic 
changes occurring mainly in two distinct types of cancer genes: oncogenes and tumor 
suppressor genes. This classification is based on the change in gene expression needed for 
carcinogenesis. Oncogenes promote cancer development in active or overexpressing form, 
whereas tumor suppressors are required to be practically inactive to promote carcinogenesis. 
Typically, oncogenes encode cell growth- and proliferation-stimulating proteins, such as 
tyrosine kinases and transcription factors. The proteins encoded by tumor suppressors 
regulate the balance between cell growth and growth-reducing signals. Inactivation of one 
allele of a tumor suppressor gene may increase cancer susceptibility, but in contrast to the 
dominantly behaving oncogenes, both alleles are assumed to be inactive before tumorigenesis 
begins (“Two-hit hypothesis”; Knudson 1971). However, recent evidence suggests that some 
such tumors may occur without a second hit (Tucker and Friedman 2002). Most cancer 
syndromes are due to inherited mutations in tumor suppressor genes. 
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The majority of CRCs occur sporadically, but it has been estimated that at least 15% of all 
CRC’s have a strong genetic predisposition (Houlston et al. 1992). The main inherited 
colorectal cancer syndromes are HNPCC and familial adenomatous polyposis (FAP) 
(Wilmink 1997). HNPCC accounts for approximately 1–6% of all CRCs and is associated 
with germline mutations in DNA mismatch repair (MMR) genes (Aaltonen et al. 1998; 
Lynch et al. 2003). FAP is estimated to account for less than 1% of all CRCs, and is due to 
mutations in the adenomatous polyposis coli (APC) gene (Groden et al. 1991). Patients 
carrying an APC mutation in their germline are prone to develop hundreds or even thousands 
of colorectal adenomas and early-onset carcinoma (Narayan and Roy 2003).  
 
Clinical features of hereditary nonpolyposis colorectal cancer 
 
HNPCC, also known as Lynch syndrome, is characterized by an autosomal dominant pattern 
of inheritance, penetrance of 80%, and diagnosis of cancer in typical sites before the age of 
50 years (Lynch et al. 1993). Most typically, HNPCC tumors are colorectal or endometrial. 
Two-thirds of the colorectal tumors are located in the proximal colon. Additionally, the risk 
for gastric, ovarian, small bowel, biliary tract and uroepithelial cancers as well as brain 
tumors is increased, but the risk is much lower than the risk for the two main HNPCC 
cancers. The endometrium is even more frequently affected than the colorectum among 
female mutation carries (Aarnio et al. 1999). The cumulative lifetime risk for CRC to the age 
of 70 years among male mutation carriers approaches 100%, whereas among females the risk 
for CRC is approximately 50% and the risk for EC approximately 60% (Aarnio et al. 1999).  
 
The cancer susceptibility in HNPCC is caused by inherited mutations in one of the MMR 
genes. MMR deficiency leads to clustering of somatic mutations particularly in short 
repetitive sequences, known as microsatellites. The resulting phenomenon in the tumor DNA, 
known as microsatellite instability (MSI), is used when diagnosing HNPCC (Rodriguez-
Bigas et al. 1997). HNPCC tumor cells appear more likely to have diploid or near-diploid 
DNA content compared to sporadic CRC cells (Kim et al. 1994). Although HNPCC-
associated colorectal cancers can be classified as poorly differentiated – which normally 
suggests that the cancer would be aggressive – HNPCC colorectal tumors have a better 
outcome than comparable sporadic tumors (Järvinen et al. 2000). Prognosis of colorectal 
 14
cancer in general depends on the stage of the tumor at the time of diagnosis, and surgery is 
the most effective treatment (Narayan and Roy 2003). 
 
Amsterdam Criteria I and II 
 
In 1991, the International Collaborative Group for HNPCC (ICG-HNPCC) standardized 
diagnostic criteria for HNPCC. To fulfill the criteria the family should include i) at least three 
affected relatives with colorectal cancer; ii) at least one should be a first-degree relative of 
the other two; iii) at least two successive generations should be affected; iv) one colon cancer 
should be diagnosed before 50 years of age; and v) FAP should be excluded (Vasen et al. 
1991). These original criteria, known as Amsterdam Criteria I, take into account only 
colorectal tumors. The revised form of HNPCC criteria, known as Amsterdam Criteria II, 
took into account endometrial, stomach, ovary, ureter or renal pelvis, brain, small bowel, 
hepatobiliary tract, and skin cancers as well (Vasen et al. 1999).  
 
 
Mismatch repair deficiency 
   
Post-replicative DNA mismatch repair in Escherichia coli 
 
When a cell divides, its genome needs to be duplicated by the replication machinery, 
consisting of a set of different proteins. DNA synthesis is also needed in many other DNA 
transactions such as in recombination- and repair-linked events. The actual copying of the 
DNA double-helix is carried out by a specific enzyme, DNA polymerase. Cells harbor 
several types of DNA polymerases for different purposes. 
 
Usually, DNA synthesis is carried out with high fidelity. Estimates for the probability of a 
single base substitution occurring during DNA synthesis vary widely, between 10–2 and 10–8 
per nucleotide (Kunkel 2004; Tippin et al. 2004). Replication errors can be either 
spontaneous or induced. When post-replicative repair mechanisms and additional 
environmental stress are absent, the spontaneous base substitution error rate in vivo ranges 
from 10–7 to 10–8. These studies have been made with bacteriophage and Escherichia coli, 
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and replication accuracy in eukaryotes is likely to be higher (Kunkel 2004). In addition to 
base substitutions, spontaneous errors in DNA synthesis include insertions and deletions of 
bases resulting from strand misalignment (Fig. 1). Rates for all types of replication errors 
vary depending on the respective polymerase and DNA sequence (Kunkel 2004). Replication 
errors can also be induced, i.e. originating as a result of environmental factors, for example 
exposure to radiation, oxygen or some other chemicals. The spontaneous deamination of 
cytosine to urasil is a common cause of errors (Tippin et al. 2004). 
 
Correction of replication errors in the commonly used prokaryotic model organism E. coli is 
carried out by the DNA mismatch repair (MMR) mechanism, alternately known as long-
patch mismatch repair, Mutator (Mut) HLS system, or mismatch proofreading system. MMR 
improves the fidelity of the replication machinery 100–1,000 fold, and therefore lowers the 
base mutation rate to one error per 1010 nucleotides (Bellacosa 2001). Inactive MMR causes 
the accumulation of mutations in the genome, and the resulting cellular phenotype is referred 
to as a "mutator phenotype" (Modrich and Lahue 1996; Schofield and Hsieh 2004). 
 
Figure 1. Emergence of insertion/deletion loops during 
DNA replication.  
Mispairing of the complementary DNA strands causes 
insertions and deletions on the newly synthesized strand, 
depending on which strand the slippage occurred. DNA 
regions containing repeat sequences are thought to be 
particularly prone to strand slippage during DNA 
replication. (Modified from Levinson and Gutman, 1987.) 
 
 
 
 
 
 
 
The MutHLS mechanism has been completely reconstructed in vitro, and is mediated by 
three homodimeric Mut proteins: MutS, MutL, and MutH (Fig. 2) (Lu et al. 1983; Lahue et 
al. 1989; Cooper et al. 1993). The first step of the repair reaction consists of the recognition 
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of the replication error, i.e. base/base mismatch or small insertion/deletion loop (IDL), and is 
carried out by the MutS homodimer (Modrich 1991). The discrimination between the 
template strand and the repairable strand in E. coli is determined by the presence of adenine 
methylation at GATC sequences (Lu et al. 1983). Methyl groups are added to all adenine 
residues at GATC sequences, but not until some time after DNA synthesis. Thus only the 
template strand will contain methylated GATC sites just behind the replisome. The 
endonuclease MutH binds the hemimethylated sequence, and nicks the newly synthesized 
strand at the unmethylated GATC sequence. MutS promotes DNA loop formation and 
interacts with MutL in the presence of ATP, which leads to the assembly of the repairosome, 
i.e. a multicomplex consisting of factors needed for excision and resynthesis of the error-
containing strand (Fig. 2) (Modrich 1991; Allen et al. 1997).  
 
 
Figure 2. Mismatch repair mechanism in 
Escherichia coli. Discrimination between the template 
and the newly synthesized strand is determined by the 
presence of methyl groups (CH3) in GATC sequences 
on the template strand. After nicking of the 
unmethylated strand by MutH, the endonucleases ExoI, 
RecJ, ExoVII, and ExoX can excise the error-
containing fragment, which could be up to 1-2 kb long. 
DNA helicase II (MutU/UvrD) and single-strand 
binding protein Ssb participate in strand removal 
(Cooper et al. 1993). (Modified from Jacob and Praz, 
2002.)  
 
 
 
 
 
 
 
MutL, an ATPase similar to MutS, has a poorly-known but central function in the repair 
reaction. It stimulates the endonuclease activity of MutH, enhances the translocation of MutS 
along DNA in search of the closest GATC site bound by MutH, and couples the mismatch 
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recognition to further repair steps (Ban et al. 1999; Hall et al. 1999). The subsequent removal 
of the newly-synthesized DNA strand can be carried out either in the 5'→3' or 3'→5' 
direction, depending on which side of the mismatch/IDL MutH has prepared the single-
strand nick. Thus either the 5'→3' or 3'→5' single-strand exonuclease is required. At least 
four exonucleases have been shown to participate in MMR in E. coli (Fig. 2) (Burdett et al. 
2001). The removed fragment is then resynthesized by DNA polymerase III holoenzyme and 
ligated by DNA ligase (Lahue et al. 1989). 
  
Mismatch repair mechanism in yeast and human 
 
After identification of the eukaryotic homologs of E. coli MutL and MutS genes, the high 
conservation rate of MMR key elements has become obvious. The function of the eukaryotic 
MMR has mostly been determined in the yeast Saccharomyces cerevisiae. The eukaryotic 
MutS and MutL homologues, which participate in MMR, and their nomenclature and 
locations in human chromosomes are listed in Table 1 (Bellacosa 2001). No indisputable 
MutH homolog has been found in eukaryotic genomes to date.  
 
Table 1. MutS/L homologs in yeast and human. 
 
E. coli 
 
S. cerevisiae 
 
H. sapiens (chromosomal location) 
MSH2 MSH2 (2p21–22) 
MSH3 MSH3 (5q11–12) 
MutS 
MSH6 MSH6 (2p16) 
MLH1 MLH1 (3p21.3) 
MLH2 PMS1 (2q31–33) 
MLH3 MLH3 (14q24.3) 
MutL 
PMS1 PMS2 (7p22) 
 
 
In eukaryotes, the MutS/L-proteins act as heterodimers. The recognition of replication error 
is carried out by two alternative heterodimers, MutSα and MutSβ, which consist of MSH2 
and MSH6 or MSH2 and MSH3, respectively (Acharya et al. 1996; Alani 1996; Genschel et 
al. 1998). The studies of yeast have demonstrated that MutSα is responsible for the binding 
of base/base mismatches (except C•C mismatches) and for the binding of IDLs consisting of 
one or a few extrahelical bases, whereas MutSβ is responsible for the recognition of IDLs 
consisting of at least two bases (Fig. 3) (Alani 1996; Habraken et al. 1996; Iaccarino et al. 
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1996; Marsischky et al. 1996). In human cells, MutSα is present at much higher levels than 
MutSβ and is mostly responsible for the recognition of base/base mismatches (Acharya et al. 
1996; Palombo et al. 1996; Genschel et al. 1998; Marra et al. 1998). Because of the partially 
redundant functions of MSH6 and MSH3, cells deficient in either one of these proteins have 
only a weak mutator phenotype. Cells deficient in both MSH3 and MSH6 have a strong 
mutator phenotype similar to cells defective in MSH2 (Marsischky et al. 1996; de Wind et al. 
1999).  
 
Figure 3. Main events in the eukaryotic mismatch repair 
reaction. The DNA error is recognized by one of the two 
MutS complexes, after which the MutL complex, 
mostly MutLα, mediates the downstream repair events. The 
helicase possibly required in the excision of  the error-
containing strand has not been identified, nor has the ligase 
needed for the filling of gaps. DNA ligase I is a reasonable 
candidate because it is often associated with polymerase δ 
(Tomkinson et al. 1998). Proliferating cell nuclear antigen 
(PCNA) is a proposed candidate for mediating strand 
discrimination (Umar et al. 1996).  
 
  
 
 
The most important eukaryotic homolog for E. coli MutL is the MLH1 protein (Table 1). 
MLH1 forms heterodimers with three different partners, PMS2, MLH3 and PMS1 (Li and 
Modrich 1995; Lipkin et al. 2000; Räschle et al. 1999, respectively). So far, only 
heterodimers consisting of MLH1 and PMS2 (referred to as MutLα), and MLH1 and MLH3 
have been shown to function in eukaryotic MMR. MutLα is involved in the repair of both 
base/base mismatches and insertion/deletion loops (Fig. 3), and is the main MutL complex in 
human cells (Li and Modrich 1995; Räschle et al. 1999). Studies in S. cerevisiae suggest that 
the yeast heterodimer of MLH1 and MLH3, together with MutSβ, is involved in the repair of 
a proportion of IDLs consisting of at least two bases (Flores-Rozas and Kolodner 1998). 
However, the contribution of MLH1-MLH3 in human MMR remains putative. MutL hetero-
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dimers are proposed to act as a "molecular matchmaker", which forces the repair reaction 
forward after the recognition of replication error (Jiricny and Nyström-Lahti 2000).  
 
On the basis of structural and sequential data, MutL homologs belong to the so-called GHKL 
ATPase superfamily, which is likely to have evolved from a common ancestor. In addition to 
the MutL homologs, the GHKL family includes DNA gyrase b, HSP90 heat shock proteins, 
and histidine kinases. These proteins contain four short conserved sequence motifs, in which 
invariant residues are suggested to have an important role in the binding and hydrolysis of 
ATP (Bergerat et al. 1997; Mushegian et al. 1997; Dutta and Inouye 2000).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. ATP binding and hydrolysis by bacterial MutL homodimer. The aminoterminal part of the MutL 
dimer is proposed to act as an ATP-driven hook that clamps the molecule onto DNA. (Modified from Ban et al. 
1999.) N, aminoterminus; C, carboxylterminus. 
 
Among the MutL homologs, only the crystal structure of 349 aminoterminal amino acids of 
E. coli MutL has been determined so far (Ban and Yang 1998; Ban et al. 1999). This analysis 
revealed that the elongated structure of MutL becomes globular upon binding of ATP or its 
analog ADPnP. Binding of the nucleotide also triggers amino-terminal dimerization of the 
MutL dimer, whereas the carboxyl-terminal interaction between the two monomers is 
assumed to be stable and independent of ATP binding (Ban and Yang 1998; Ban et al. 1999). 
The ATP→ADP cycle of MutL is represented in Figure 4. The conformational changes in the 
N-terminus have been demonstrated also with human MutLα, and binding and hydrolysis of 
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the ATP nucleotide have been shown to be critical for the stability and function of the 
heterodimer (Räschle et al. 2002). Although the ATP binding/hydrolysis motifs of human 
PMS2 are similar to those of MLH1, the ATPase capacity of PMS2 is not critical to the 
heterodimer (Räschle et al. 2002).  
 
Although the human MMR reaction can be reconstructed in vitro in cell extracts (Holmes et 
al. 1990), the mechanism for discrimination between template and nascent DNA strands 
remains obscure. DNA methylation, responsible for strand discrimination in E. coli, is 
excluded in humans (Drummond and Bellacosa 2001). One suggested factor in strand 
discrimination is the proliferating cell nuclear antigen (PCNA), which is necessary for DNA 
replication. PCNA is loaded onto DNA by replication factor C (RFC), and it forms a sliding 
clamp which diffuses along the DNA and provides processivity to the replicative polymerase 
(Fig. 3) (Hingorani and O'Donnell 2000). PCNA was originally found to interact with MLH1 
in a yeast two-hybrid screen (Umar et al. 1996). Later it was shown to also interact with 
PMS2 (Gu et al. 1998) and MutSα/β (Clark et al. 2000). PCNA has been suggested to 
recognize the free DNA termini resulting from the replication machinery, and to guide the 
mismatch repair proteins to the newly synthesized strand at an early stage of the MMR 
process (Umar et al. 1996).  
 
The signalling between mismatch recognition and further steps in repair is mostly ATP-
dependent. MutSα/β is able to bind mismatches and IDLs with strong affinity in its ADP-
bound state, and the damage recognition induces the ADP→ATP exchange (Gradia et al. 
1997; Wilson et al. 1999). Apparently, the ATP-bound state of MutSα/β forms a clamp 
which dissociates from the mismatch and diffuses along the DNA backbone in a hydrolysis-
independent manner (Gradia et al. 1999). Several studies have shown that the interaction 
between MutS- and MutL-heterodimers requires ATP, and it happens only when attached to 
the DNA (Blackwell et al. 2001; Plotz et al. 2002; Räschle et al. 2002).  
 
The downstream components of MMR have been characterized much more poorly in 
eukaryotes than in E. coli. Putative candidates for the excision and resynthesis of the error-
containing strand are the 5'→3'-active exonuclease EXO1, the single-strand binding 
replication protein A (RPA), PCNA, RCF, polymerase δ and perhaps also ε, DNA ligase I, 
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and an unidentified helicase (Fig. 3) (Jiricny 1998; Jiricny and Nyström-Lahti 2000). 
Because the repair reaction is bidirectional, a 3'→5' exonuclease is also required. One 
suggestion is that the ATP-bound form of MutSα induces a conformational change of the 
replicative polymerase in such a way that DNA synthesis is stopped and the 3'→5' 
exonuclease capability of the polymerase is activated, resulting in the removal of the error-
containing strand (Gradia et al. 1999; Fishel 1999). 
 
Role of MMR proteins in DNA damage signalling  
 
Although the MMR machinery repairs only DNA mismatches and short IDLs, the MMR 
proteins are also involved in apoptosis and checkpoint activation in response to various forms 
of DNA damage. It is not well understood how the MMR proteins participate in DNA 
damage signalling, but it seems that without MMR, the cells with damaged DNA will not 
undergo apoptosis because of a failed connection between the MMR and G2/M cell cycle 
checkpoint (Hawn et al. 1995). 
 
Cytotoxicity of some alkylating or anti-cancer agents requires functional MMR (Branch et al. 
1993; Kat et al. 1993). N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), N-methyl-N-
nitrosourea (MNU) and their analogues in clinical use (temozolomide and dacarbazine) cause 
DNA damage by methylating the O6 position of guanine to form O6-methylguanine. As a 
normal cellular response to alkylating agents, MMR proteins recognize the DNA damage and 
mediate the induction of apoptosis (Branch et al. 1993; Kat et al. 1993). Apparently, MMR is 
required for p53 phosphorylation in response to DNA alkylator damage (Duckett et al. 1999). 
UVB-induced apoptosis and p53 phosphorylation at serine 15 are remarkably diminished in 
cell lines defective for MSH2 (Peters et al. 2003). MMR is also involved in the induction of 
the p53-related transcription factor p73: cisplatin-induced accumulation of p73 depends on 
functional MLH1 (Gong et al. 1999), and treatment with cisplatin induces an interaction 
between PMS2 and p73, which leads to the stabilization and activation of p73 (Shimodaira et 
al. 2003). Moreover, the MMR machinery was reported to be required in the activation of the 
S-phase checkpoint in response to ionizing radiation (Brown et al. 2003).  
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The function of MMR proteins in the repair process and DNA damage signalling may 
involve different molecular processes. Consistent with this, subnormal levels of MLH1 have 
been reported to be enough for efficient MMR, while the checkpoint activation requires a full 
level of MLH1 (Cejka et al. 2003).  
 
Replication errors as a driving force in CRC tumorigenesis 
 
Mutation rates in MMR-deficient cells are 100–1,000 fold that of normal cells. In the absence 
of any selective pressure, mismatches and insertions/deletions should occur at similar rates in 
any coding or noncoding DNA region, depending only on the type of sequence. DNA regions 
containing repetitive sequences, for example “microsatellites”, are particularily prone to 
strand slippage during DNA replication (Fig. 1) (Levinson and Gutman, 1987). MMR 
deficiency can be verified from cells by observing insertions/deletions in these microsatellite 
sequences, a phenomenon called MSI (Aaltonen et al. 1994). 
 
Repetitive sequences can exist within all types of genes, also in those important in regulating 
normal cellular growth and proliferation. When certain tumor suppressors or oncogenes are 
affected by frame-shift mutations in such sequences, a cell has a selective advantage 
compared to normal cells (Fig. 5). Thus, the genetic instability leads to an evolutionary 
process which can start the formation of a tumor, i.e. a large population of malignant cells.  
 
The MMR-dependent CRC development differs from the general model of CRC 
development, which is one of the best characterized models of tumor progression (Fig. 5). 
According to the general model, the development of a malignant tumor is initiated by 
alterations in genes such as APC or β-catenin (CTNNB1), and thus called as APC/β-catenin 
pathway (Vogelstein and Kinzler 1993). In the MMR pathway, a complex signalling network 
is established among inactivated and activated cellular pathways caused by accumulation of 
replication errors and other genetic changes. Genes which are mutated at different stages of 
CRC development encode proteins involved e.g. in signal transduction (TGFβRII, IGFIIR, 
PTEN), apoptosis and inflammation (BAX, CASP1), transcription regulation (TCF4), and 
DNA repair (MSH3, MSH6, MBD4), and are known as “target genes” (Peltomäki  2001a; 
Jacob and Praz 2002) (Fig. 5). Some of these genes, e.g. the MMR genes MSH6 and MSH3, 
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are commonly mutated in micro-satellite-unstable cancers, whereas others, such as TGFβRII 
and TCF4, are typically mutated in gastrointestinal but not in endometrial cancers (Duval et 
al. 1999; Markowitz et al. 1995; Malkhosyan et al. 1996; Peltomäki  2001a). 
 
In a human cell, both alleles of an MMR gene need to be inactivated before the loss of the 
MMR activity. This is consistent with the "two-hit hypothesis" (Knudson 1971), which 
concerns tumor suppressor genes in general: in hereditary cancers, the first "hit" is a germline 
mutation in one allele, and the second "hit" is a somatic mutation or loss of heterozygosity 
(LOH) affecting the other allele. In sporadic cancers, both hits are somatic.   
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Two pathways to colorectal cancer. The APC/β-catenin pathway (top) is possibly the best 
characterized pathway from normal epithelium to cancer (Vogelstein and Kinzler 1993). The mismatch repair 
deficiency-driven pathway (bottom) is initiated by mutations in one or few mismatch repair genes, followed by 
microsatellite instability for example in TGFβRII, BAX, MSH6, MSH3, TCF4, IGFIIR, AXIN2, CASP1, MBD4, 
PTEN, and RIZ genes (Peltomäki, 2001a). (Modified from Narayan and Roy 2004.)  
 
Constitutive lack of mismatch repair 
 
There is an important difference whether the loss of tumor suppressor activity is acquired 
only in a particular tissue, or is absent from the first stage of embryogenesis throughout the 
entire body. Timing of the inactivation has a huge impact on the resulting phenotype, and as 
in the case of MMR inactivity, on the resulting genotype as well.  
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There are some descriptions of individuals who are homozygous for an MMR gene mutation 
or carry germline mutations in both alleles of an MMR gene (Table 2). Usually such 
individuals are offspring from consanguineous marriages within HNPCC families. A 
constitutive MMR-deficiency in humans is generally associated with hematological 
malignancies and features of de novo neurofibromatosis type 1 syndrome (NF1) such as café-
au-lait spots, axillary freckles, and neurofibromas. Apparently, the constitutive lack of MMR 
generates genetic instability in genes which are structurally the most fragile (such as the NF1 
gene) or expressed in rapidly proliferating cells (such as hematopoietic genes) (Andrew 
1999; Peltomäki 2001a). However, there are relatively few gastrointestinal malignancies 
found in individuals who carry bi-allelic germline MMR gene mutations. This may be due to 
early ages at the time of diagnoses, and death before gastrointestinal cancer develops. All the 
reported colorectal malignancies have occurred after the age of nine years, whereas many of 
the homozygous patients have already died before the age of five.   
 
The development of hematological malignancies in homozygous patients is consistent with 
the phenotypes of MMR-deficient mice strains (Table 3) (Wei et al. 2002). Homozygous 
mice, which are used as mouse models for HNPCC, develop mostly lymphomas at 
approximately 2–5 months of age (Baker et al. 1995; de Wind et al. 1995; Baker et al. 1996; 
Edelmann et al. 1997). Gastro-intestinal carcinomas are rare and appear in older mice, 
similarly to the characteristics of humans carrying bi-allelic MMR gene mutations. In 
contrast to heterozygous HNPCC patients, heterozygous mice do not develop gastrointestinal 
malignancies. This phenomenon is possibly due to the short lifetime of rodents, which does 
not allow the occurrence of the "second hit" needed for inactivation of the appropriate MMR 
gene (de Wind et al. 1995). It has been suggested that the differences in tumor spectra 
between MMR-deficient humans and mice are partly due to differences in the critical target 
sequences (Jacob and Praz 2002).  
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Table 2. Bi-allelic germline mutations in MMR genes.  
 
Affected 
gene 
 
 
Mutation(s) 
 
No of 
individuals1
 
Clinical characteristics of 
homozygous individuals 2
Clinical 
characteristics  
of the family 
 
 
Reference 
MLH1 c. 676C>T 
(R226X) 
3 Chronic myeloid leukemia (1 yr); 
Non-Hodgin's lymphoma (3 yr); 
Acute leukemia (2 yr);  
Features of NF1 
Typical HNPCC 
family 
Ricciardone 
et al. 1999 
MLH1 c. 199G>T 
(G67W) 
2 Non-Hodgin's lymphoma (2 yr); 
Acute myeloid leukemia (6 yr); 
Medullo-blastoma (7 yr);  
Features of NF1 
Typical HNPCC 
family 
Wang et al. 
1999 
PMS2 c. 2361-
2364del 
+ 1221del 
2 Glioma (14 yr); CRC (18 yr); 
Neuroblastoma (13 yr) 
No confirmed 
cancer cases 
De Rosa et 
al. 2000 
PMS2 c. 1169ins20 2–3 3 CRC (16 yr); Ovarian cancer (21 
yr); EC (23 yr); Brain tumor (24 yr); 
Astrocytoma (7 yr); Acute lymphoid 
leukemia (4 yr); Features of NF1 
One CRC Trimbath et 
al. 2001 
MLH1 c. 1732-
1896del  
(exon 16) 
1 Glioma (4 yr); Features of NF1 Not reported Vilkki et al. 
2001 
MSH2 Splice-site 
mutation g>a 
at 1662–1 bp 
1 Acute lymphoid leukemia (4 yr); 
Features of NF1 
No cancer cases Whiteside 
et al. 2002 
MSH2 Del of exons 
1–6 
+ 1-bp del at 
codon 153 
2 Lymphoma (1 yr);  
Glioblastoma (3 yr) 
Two EC’s; one 
astrocytoma 
Bougeard 
et al. 2003 
PMS2 R802X 3 Non-Hodgkin’s lymphoma (10 yr); 
Brain tumor (8 yr, 14 yr);  
Features of NF1  
No cancer cases De Vos et 
al. 2004 
MLH1 c. 2059C>T 
(R687W) 
3 CRC (9yr, 11yr); 
Features of NF1 
One CRC; one 
gastric cancer 
Gallinger et 
al. 2004 
MSH6 3385-3390del 
+insCTT 
1 Glioma (10 yr); CRC (12 yr); 
Features of NF1 
No confirmed 
cancer cases 
Menko et 
al. 2004 
1 Number of individuals homozygous for the mutation; 2 The numerals in parenthesis indicate the age (years) of 
the patient at the time of diagnosis; 3 The homozygous status of one patient could not been verified because of  
early death at the age of 4. 
 
Table 3. Characteristics of mice strains deficient for the most common HNPCC genes.  
Tumors  
 
Genotype 
 
50% survival 
(months) 1
Spectrum Incidence 
 
Fertility 
(male/female) 
 
 
References 
Mlh1−/− 6 Lymphoma, gastro-
intestinal, skin, others 
High −/− Baker et al. 1996;  
Prolla et al. 1998 
Msh2−/− 6 Lymphoma, gastro-
intestinal, skin, others 
High +/+ de Wind et al. 1995; 
Reitmair et al. 1995;  
de Wind et al. 1998;  
Msh6−/− 11 Lymphoma, gastro-
intestinal, others 
High +/+ Edelmann et al. 1997; 
de Wind et al. 1999 
Pms2−/− 10 Lymphoma, sarcoma High −/+ Baker et al. 1995;  
Prolla et al. 1998  
 1 normal lifespan approximately 16–18 months  
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Germline mutations associated with HNPCC 
 
Variety of HNPCC genotypes and phenotypes 
 
InSiGHT maintains a database which contains germline mutations found in HNPCC or 
putative HNPCC families (http://www.InSiGHT-group.org/). At present, the database 
includes 448 MMR gene mutations found in 748 families from different parts of the world 
(as of July 31st, 2003) (Peltomäki and Vasen 2004). The majority of the mutations involve 
MLH1 (50%), MSH2 (39%), or MSH6 (7%) (Table 4). PMS2 (1%) has also been linked to 
HNPCC susceptibility, whereas the roles of MLH3 and PMS1 are less clear (Peltomäki and 
Vasen 2004). The pathogenic significance of the 16 reported MLH3 mutations has remained 
obscure, and in a family in which PMS1 variation has been reported, HNPCC also segregates 
with a large MSH2 deletion, which is most probably the susceptibility mutation in this family 
(Liu et al. 2001).  
 
The HNPCC-associated mutations are generally scattered throughout the coding sequences 
and exon/intron boundaries of MMR genes (http://www.InSiGHT-group.org/). Exons 1 and 
16 in MLH1, exons 3 and 12 in MSH2, and exon 4 (a very large exon) in MSH6 represent 
some kind of mutation hot-spots (Peltomäki and Vasen 2004). Almost all (13/16) MLH3 
germline mutations are located in only one exon (1) (Wu et al. 2001; Liu et al. 2003). This 
exon is proposed to code a domain which interacts with MLH1, the interaction partner of 
MLH3 (Kondo et al. 2001).  
 
The majority (81%) of MMR gene mutations are unique, i.e. specific to only one HNPCC 
family (Peltomäki and Vasen 2004). Most are nonsense or frame-shift mutations and cause 
truncation and loss-of-function of the respective polypeptide (Table 4). However, a 
significant proportion of mutations, approximately 30% of MLH1 and MSH6, and nearly 
90% of MLH3 mutations, are of the missense type. Because of the genetic diversity of 
HNPCC-predisposing mutations, the search for a predisposing mutation in a new HNPCC 
family generally requires many different time-consuming methods.  
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Approximately 30% of the HNPCC families which fulfil the Amsterdam criteria I fail to 
show a mutation in any known MMR gene (Liu et al. 1996; Peltomäki 2001b). Recent 
studies have shown that an MMR defect can frequently be caused by large genomic deletions 
and uncharacterized mutations, which lead to loss of expression of an MMR gene but are 
difficult to identify (Charbonnier et al. 2002; Wang et al. 2002). 
 
Table 4. Germline alterations in different MMR genes, and the proportions of different 
types of mutations (http://www.InSiGHT-group.org/; Peltomäki and Vasen 2004).  
Gene Proportions of different mutation types 
 
Total no of 
mutations   
Nonsense 
 
Frameshift 
 
Missense 
 
In-frame 1
 
Other 
No of non-
pathogenic 
variants 
MLH1 225 (50%) 11% 44% 32% 10% 3% 27 
MSH2 175 (39%) 49% 19% 18% 9% 5% 28 
MSH6 32 (7%) 22% 37% 38% − 3% 43 
MLH3 16 (3%) − 13% 87%  − − 5 
PMS2 5 (1%) 20% 40% 20% 20% − 5 
PMS1 1 (<1%) 100%  − − − − − 
Total 448 (100%)       
 1 in-frame insertions and deletions 
 
The typical HNPCC phenotype is usually associated with MLH1 and MSH2 mutations (Liu et 
al. 1996; Nyström-Lahti et al. 1996). Sixty-three % of the families with an identified MLH1 
mutation and 50% of the families with an MSH2 mutation are reported to fulfill the stringent 
Amsterdam criteria I, whereas less than 20% of MSH6 and PMS2 families fulfill the criteria 
(Peltomäki and Vasen 2004). MSH2 mutations appear to be associated with a higher risk of 
development of extracolonic cancers than are MLH1 mutations (Vasen et al. 1996), and 
furthermore, the lifetime risk of any cancer may be higher among MSH2 mutation carriers 
than among MLH1 mutation carriers (Vasen et al. 2001). Remarkably, among female MSH6-
mutation carriers, the risk for CRC is notably lower, but the risk for endometrial cancer 
significantly higher than among MLH1 and MSH2 mutation carriers (Hendriks et al. 2004). 
Overall, the risk for HNPCC-related tumors is significantly lower in MSH6-mutation-
associated families than in families with mutations in either MLH1 or MSH2 (Hendriks et al. 
2004). In MSH6-mutation carriers, the cumulative risk for colorectal carcinoma was 69% for 
men, 30% for women, and 71% for endometrial carcinoma at 70 years of age (Hendriks et al. 
2004). In individuals carrying mutation in either MLH1 or MSH2, the risks are 100%, 50%, 
and 60%, respectively (Aarnio et al. 1999).  
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MSH2 is primarily affected in the HNPCC-related Muir-Torre syndrome, which is charac-
terized by the occurrence of sebaceous gland tumors in addition to HNPCC-type 
malignancies (Kruse et al. 1998). Turcot syndrome, which is characterized by the occurrence 
of brain tumors together with colon carcinoma, involves mutations in the MLH1 and PMS2 
genes (Hamilton et al. 1995). Individuals carrying bi-allelic mutations in a MMR gene 
typically have hemato-logical malignancies and features of NF1 (Table 2).   
 
The MMR gene involved in HNPCC predisposition appears to have an effect on the disease 
phenotype. However, the role of the type and site of the mutations is less clear. In particular, 
missense mutations appear to be associated with a wide range of clinical phenotypes 
(Peltomäki et al. 1997). The severity of the resulting disease phenotype may partly depend on 
the ability of the mutant MMR proteins to exert a dominant negative effect on the MMR 
mechanism (Jäger et al. 1997). Missense mutations, which are shown to be MMR-proficient 
in functional assays, are often associated with mild or atypical HNPCC phenotypes (Ellison 
et al. 2001; Nyström-Lahti et al. 2002; Kariola et al. 2002, 2004). A splice-site mutation in 
MLH1, which silences the affected allele, is associated with reduced frequency of 
extracolonic cancers (Jäger et al. 1997). An analysis of Finnish HNPCC families suggested 
that nontruncating aminoterminal MLH1 mutations were associated with milder phenotypes 
than nontruncating mutations affecting the carboxylterminus (Peltomäki et al. 2001). 
However, the association between different HNPCC genotypes and phenotypes is poorly 
understood. 
 
Cancer-predisposing mutations in MLH1 
 
The human MLH1 gene includes 19 exons, and encodes a protein consisting of 756 amino 
acids (∼86 kDa) (Han et al. 1995). The resulting MLH1 protein can be divided into two 
functionally relatively divergent domains: the aminoterminal domain, which is responsible 
for ATP binding and hydrolysis, and the carboxylterminal domain, which provides an 
interaction site needed for heterodimerization (Figure 6) (Tran and Liskay 2000; Räschle et 
al. 2002; Guerrette et al. 1999; Kondo et al. 2001). Interestingly, the three alternative 
heterodimerization partners, PMS2, MLH3, and PMS1, share a common interaction site in 
MLH1 (Kondo et al. 2001).  
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MLH1 is the most common susceptibility gene in HNPCC. While over 50% of germline 
MLH1 mutations lead to truncation of the polypeptide, 32% of mutations are of the missense 
type (Table 4) (Peltomäki and Vasen 2004). The missense mutations associated with HNPCC 
are mildly clustered in the two functional domains of the MLH1 polypeptide (Fig. 6) 
(http://www. InSiGHT-group.org/).  
There are only a few widespread recurring MLH1 mutations, namely MLH1-del616, in which 
one lysine residue is deleted from a repeat of three lysines in exon 16; MLH1-K618A, in 
which one of the three lysines is substituted by alanine; and MLH1-T117M, in which a 
metionine replaces a threonine residue in exon 4 (Peltomäki and Vasen 2004; 
http://www.InSiGHT-group.org/).  
 
MLH1 mutations account for over 90% of all Finnish HNPCC-associated mutations 
identified (Holmberg et al. 1998). This is likely due to two MLH1 “founder” mutations, a 
3.5-kb genomic deletion affecting exon 16 and a splice acceptor site mutation of exon 6, 
which together account for 63% of all Finnish HNPCC mutations (Nyström-Lahti et al. 1995; 
Moisio et al. 1996). Only two MLH1 missense mutations (MLH1-I107R and MLH1-R659P) 
have been found in Finland (Nyström-Lahti et al. 1996).  
 
 
 
 
 
 
 
 
igure 6. Distribution of missense mutations (black triangles) in the MLH1 polypeptide.  
he four ATP binding/hydrolysis motifs (black) correspond the amino acids 31–43, 63–68, 97–107, and 146–
47. The PMS2/ MLH3/PMS1 interaction domain (striped) is located between the amino acids 492/506 and 
43. The final 13 amino acids are identical in human and yeast MLH1 and comprise the carboxylterminal 
omology motif (CTH) with unknown function (Pang et al. 1997). The numbers at the bottom of the figure 
ow the cor-responding exons in the MLH1 cDNA.  
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Interpretation of pathogenicity of MMR gene mutations 
 
Clinical investigations of patients and their families 
Proper information about the pathogenicity of an inherited gene variant is essential. It is 
enerally accepted that effective genetic testing for HNPCC requires determination of 
nctional significance of the minor MMR gene variants, such as missense mutations. 
genic nontruncating variants 
an be difficult (http://www.InSiGHT-group.org/). Segregation studies can be used to 
orphisms. If an identified amino acid 
fils 
e Amsterdam Criteria; ii) the individual has two HNPCC-related malignancies, including 
unstable; low, if 1/5 of the markers show instability; and stable, if none of the markers used 
g
fu
However, the differentiation between pathogenic and non-patho
c
distinguish pathogenic missense mutations from polym
change can be shown to segregate with the disease phenotype in the family, it suggests – but 
does not prove – that an alteration is a pathogenic mutation. Unfortunately, insufficient 
family size and unavailability of clinical samples often prevent such segregation studies.  
 
Since HNPCC is considered as an MMR deficiency syndrome, one important phenotype 
associated with pathogenicity of the mutation is MSI in the tumor sample. MSI analysis is 
often used for choosing putative HNPCC patients for further studies. The Bethesda 
guidelines, developed by InSiGHT, recommend testing colorectal tumors for MSI, if any of 
the following criteria is fulfilled: i) an affected individual belongs to a family which ful
th
synchronous or metachronous CRCs or associated endometrial cancers; iii) the individual 
with CRC has a first-degree relative with CRC and/or HNPCC-related extracolonic 
carcinoma and/or colorectal adenoma, and one of the tumors is diagnosed at an age < 
45years, and adenoma < 40 years; iv) the individual has CRC or endometrial carcinoma that 
was diagnosed at age < 45 years; v) the individual has right-sided CRC with an 
undifferentiated pattern on histopathology diagnosed at age < 45 years; vi) the individual has 
signet ring cell-type CRC that was diagnosed at age < 45 years; or vii) the individual has 
adenomas diagnosed at age < 40 years (Rodriguez-Bigas et al. 1997; Lynch et al. 2003).   
 
The widely advocated National Cancer Institute (NCI) microsatellite marker panel contains 
three dinucleotide markers and two mononucleotide markers (Dietmaier et al. 1997). The 
MSI phenotype is classified as high if at least 2/5 or 40% of microsatellite markers used are 
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are unstable. MSI occurs in 15-25% of sporadic colorectal and endometrial cancers as well, 
and consequently, at least 90% of CRCs classified as MSI-high are sporadic cancers 
Kuismanen et al. 2000; Jass et al. 2002). MSI  in sporadic cancers is mostly caused by 
R gene. Moreover, if the predisposing mutation has not been found, the 
bsence of an MMR protein indicates a mutation in the corresponding gene. It seems that 
(
methylation of the promoter and silencing of the MLH1 gene (Kane et al. 1997). The MSI 
status in an HNPCC tumor is dependent on the associated MMR gene: MLH1, MSH2, and 
PMS2 mutations are usually associated with high MSI, whereas MSH6 and MLH3 mutations 
are associated with variable MSI, from microsatellite stable (MSS) to high MSI (Peltomäki 
and Vasen 2004).  
 
In addition to MSI study, immunohistochemical (IHC) analysis with antibodies that 
recognize MMR proteins has been utilized in HNPCC diagnostics for several years. Many 
systematic studies for the ability to detect MMR deficiency from HNPCC tumors with IHC 
has been published (Müller et al. 2001; Lindor et al. 2002; Wahlberg et al. 2002). Lack of an 
MMR protein in the tumor tissue indicates pathogenicity of the mutation in the 
corresponding MM
a
while MSH2 staining is technically reliable and succesful in most laboratories, MLH1 
staining is more variable and often difficult to interpret (Müller et al. 2001; de la Chapelle 
2002). In the study of Lindor et al. (2002), MSI and IHC for MLH1 and MSH2 proteins were 
analyzed for over 1,000 colorectal cancer patients. HNPCC comprised 31% of MSI-positive 
tumors. IHC analysis of MLH1 and MSH2 showed 92% sensitivity and 100% specifity for 
MSI, which means that all tumors deficient in either MLH1 or MSH2 were MSI-positive, 
whereas 8% of MSI-positive tumors showed normal MLH1 and MSH2 staining in IHC 
analysis. This is consistent with the variable effects of different mutations on the resulting 
protein: missense mutations, minor in-frame deletions or insertions, or mutations that 
truncate the encoded protein near the carboxyl-terminal end, may display normal staining in 
IHC analysis (Wahlberg et al. 2002). 
 
Functional characterization of mutations found in putative HNPCC patients 
Several methods have been established which provide information about the effect of 
HNPCC mutations on the function of the respective polypeptide. Such functional 
characterization of MMR gene variants can be unambiguous in the case of mutations that 
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bring about premature termination of translation. However, mutations that do not cause 
premature termination are more difficult to interpret. Thus, functional assays particularly 
cus on such mutations.  
ystem of S. cerevisiae and that any mutation that affects important 
nctional domains of MLH1 would abolish the interactions between the human and yeast 
m the study was that in diploid heterozygous yeast strains the mutator effect 
e wild-type yeast allele, not from reduced MMR efficiency. An 
protein as a “prey”. The heterodimers were precipitated with glutathione beads and 
fo
 
One of the earliest functional assays is based on the dominant mutator effect of human 
MLH1 expressed in S. cerevisiae (Shimodaira et al. 1998). In the assay, human wild-type 
MLH1 and some polymorphism-like alterations interact with yeast MMR machinery and 
interfere with its function. The resulting MMR deficiency can be detected with a reporter 
gene which contains repetitive sequences. This assay presupposes that human MLH1 protein 
interferes with the MMR s
fu
proteins.   
  
In the second yeast-based assay, mutations are introduced into the S. cerevisiae genome. The 
mutations studied with this assay affected mostly the amino-terminus of the Mlh1 protein and 
mimicked MLH1 mutations found in HNPCC patients (Shcherbakova and Kunkel 1999). 
Haploid yeast strains carrying these mutations were tested for a mutator phenotype. Diploid 
yeast strains heterozygous for the mutation were also analysed. An interesting finding 
derived fro
resulted from the loss of th
advantage of this method is its homologous conditions: the yeast Mlh1 protein is analyzed in 
the yeast MMR system. However, its weakness is that only the amino acid residues which are 
conserved between human and yeast MLH1 can be studied. The principles of the assay 
described above were later utilized and modified in the study of Ellison et al. (2001). They 
constructed human-yeast hybrid MLH1 and MSH2 proteins where the residue under study 
was not conserved between human and yeast.  
 
The effects of HNPCC-related MSH2 and MLH1 mutations on the assembly of MutSα 
and MutLα, respectively, have been determined using glutathione-s-transferase (GST) fusion 
protein interaction assays (Guerrette et al. 1998, 1999). The assay relied on the use of a GST 
fusion protein expressed in E. coli as a “bait” and an in vitro transcribed and translated 
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fractionated with gel electrophoresis. Unfortunately, the MMR gene mutations, which have 
no effect on the interaction but affect the polypeptide in some other way, don’t produce a 
athogenic phenotype in this assay. 
he in vitro MMR assay is possibly the most sophisticated method for testing the effect of 
ts, which 
ck these heterodimers (Li and Modrich 1995; Iaccarino et al. 1996; Räschle et al. 1999; 
tion is unclear. Surprisingly, the MLH1 variants 
hich carried amino-terminal mutations were the most defective in interaction with both 
p
 
The effects of mutations in MLH1, MSH2, and MSH6 genes on the ability of the protein 
variants to interact with their counterparts have also been studied using a coimmuno-
precipitation method. In this assay, the recombinant human MMR protein variants were 
incubated with their heterodimerization partners. The heterodimers were then precipitated 
with agarose beads covered by appropriate antibodies, and the interactions were verified with 
Western blot analysis (Nyström-Lahti et al. 2002; Kariola et al. 2002, 2003, 2004). 
 
T
human MMR-gene mutations on the repair reaction, since it studies the phenotypic con-
sequences of HNPCC mutations in a homologous human MMR system (Nyström-Lahti et al. 
2002). The assay was originally developed from in vitro MMR assays, where human nuclear 
extracts were analysed for their ability to correct DNA heteroduplexes (Holmes et al. 1990; 
Thomas et al. 1991). Later, MutSα and MutLα proteins, either recombinant or extracted 
from human cells, have been shown to complement the MMR capacity in cell extrac
la
Drummond et al. 2001). Before the present study, the in vitro MMR assay has been used to 
study the MMR capability of four MLH1 missense mutations and two large in-frame 
deletions in MLH1, as well as some MSH6 and MSH2 missense mutations (Nyström-Lahti et 
al. 2002; Kariola et al. 2002, 2003, 2004).  
 
Kondo et al. (2003) have recently used a two-hybrid yeast assay to determine the 
pathogenicity of a large number of HNPCC-associated MLH1 mutations. They tested the 
ability of MLH1 variants to interact with its counterpart PMS2 and with its propable 
counterpart EXO1 (Tran et al. 2001). The EXO1-interaction region is between the amino 
acids 411 and 650 in the MLH1 carboxylterminus (Schmutte et al. 2001). However, EXO1 is 
also shown to interact with MSH2 (Schmutte et al. 2001) and the importance of the MLH1- 
EXO1 interaction for the human MMR reac
w
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PMS2 and EXO1 in the two-hybrid yeast assay (Kondo et al. 2003). This result is 
inconsistent with previous data, which suggest that both PMS2 and EXO1 interaction regions 
in MLH1 are in the carboxylterminus (Guerrette et al. 1999; Kondo et al. 2001). 
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AIMS OF THE PRESENT STUDY 
he present study was undertaken to evaluate the functional significance of 31 non-
uncating MLH1 germline alterations. The alterations were found in putative HNPCC 
milies and collected for functional characterization through an international HNPCC 
ons were selected from the InSiGHT database. 
he aims of the present study were as follows: 
rotein 
ation with clinical data available from these 
milies to identify genotype-phenotype correlations  
 
 
T
tr
fa
collaboration. In addition, three MLH1 alterati
 
T
 
– to determine whether the MLH1 gene variants found in suspected HNPCC families are 
pathogenic 
– to find out whether these alterations affect the function and/or quantity of the MLH1 
p
– to correlate the genetic and biochemical inform
fa
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MATERIALS AND METHODS 
rmline MLH1 mutations (IIV) 
rmline alterations, including 28 missense and six 
in-frame deletion type changes. Thirty-one alterations were found in suspected HNPCC 
amilies, and three alterations were selected from the InSiGHT database.  
tive nucleotide and coding 
hanges are listed in Table 5. The mutations are referred to in the text mostly by their amino 
inus, 
hich contains the region where MLH1 interacts with its counterparts, PMS2, MLH3, and 
 in the tumors. The clinical 
haracteristics and results of the molecular studies are summarized in Table 5. 
 
 
Study subjects: ge
 
The present study is based on 34 MLH1 ge
f
 
The mutations, their locations in the MLH1 gene, and the respec
c
acid changes. The 34 alterations are scattered throughout the MLH1 polypeptide, but are 
mainly clustered in its aminoterminus, which is responsible for ATP binding and hydrolysis 
(Ban et al. 1999; Tran and Liskay 2000; Räschle et al. 2002), and in the carboxylterm
w
PMS1 (Fig. 7) (Guerrette et al. 1999; Lipkin et al. 2000; Kondo et al. 2001). The MMR 
capability of protein variants C77R, S93G, I107R, del633-663, and R659P had been 
functionally investigated in a previous study (Nyström-Lahti et al. 2002), but were included 
in the present study for further functional characterization. 
 
Thirty-one germline MLH1 alterations were found in suspected HNPCC families and 
collected for functional studies through an international collaboration. Some of the alterations 
are already included in the InSiGHT database, and some are novel. The gene variant carriers 
and their kindreds have been subjected to clinical and molecular studies such as MSI and 
immunohistochemical analysis of the MMR proteins
c
 
One MLH1 mutation, c. 1942C>T (P648S), was found in a typical HNPCC family with 10 
colorectal cancer patients (Bisgaard et al. 2002). A child conceived from a consanguineous 
mating between first cousins was found to be homozygous for the mutation and to display 
mild features of neurofibromatosis type 1 (NF1) – two café-au-lait spots and a skin tumor – 
but no axillary freckles or hematological malignancies.  
 37
Table 5. Genetic and clinical data of the MLH1 alterations under study. The amino acid 
changes are predicted based on the nucleotide changes.  
MLH1 
variant 
 
Exon 
Nucleotide 
change in cDNA 
Amino acid 
change 
Conserv. 
of aa1
Familial 
Background2
Index 
Patients3
Mean age of 
onset4
MSI 
status5
IHC of 
MLH16
P28L 1 c. 83C>T Pro → Leu Yes +ACI (1) 
−ACI (1) 
CRC/30 
CRC/27 
37 
29 
High 
High 
N.D. 
No loss 
A29S 1 c. 85G>T Ala → Ser No +ACI (1) CRC/37 47 High Loss 
TSI45–47CF 2 c. 133-141del 
ACAAGTATT 
ins TGTTTT 
Thr, Ser, Ile
→ Cys, Phe
Yes (T, I) 
No (S) 
+ACI (1) CRC/32 43 N.D. N.D. 
D63E 2 c. 189C>A Asp → Glu Yes −ACI
G67R 2 c. 199G>A Gly → Arg Yes −ACI
 (1) CRC/44 41 High Loss 
 (1) CRC/36 36 High N.D. 
Loss 
N.D. 
 (1) CRC/22 32 High N.D. 
L  
I107R 4 c. 320T>G Ile → Arg Yes +ACI 
CRC/30 54 High Loss 
L155R 6 Leu → Arg Yes +ACI (1) CRC/33 41 High Loss 
 
 No loss 
No loss 
No loss 
11 c. 988-
K443Q 12 c. 1327A>C Lys → Gln Yes −ACI (1) 
L550P 14 c. 1649T>C Leu → Pro No −ACI (1) 
c. 18 TG 
c  
delAAG 
K618A 16 c. 1852-1853AA>GC Lys → Ala No −ACI (5) 
 
CRC/76 L  
No loss 
Loss 
No loss 
No loss 
663 17 c. l 
No  
P  No  
Pro 
+ACI (1) 
R659P 17 c. 1976G>C Arg → Pro Yes +ACI (1) 
R659Q 17 c. 1976G>A Arg → Gln Yes +ACI 
A681T 18 c. 2041G>A Ala → Thr Yes −ACI (1) 
−ACI (2) 
+ACI (2) 
CRC/65 
E 9 
CRC/43 57 
L  
High 
High 
No loss 
Loss 
Loss 
del71 3 c. 211-213delGAA Del Glu No −ACI (1) 
+ACI (1) 
CRC/24 
CRC/19 
27 
36 
High 
High 
C77R 3 c. 229T>C Cys → Arg Yes +ACI
F80V 
K84E 
3 c. 238T>G Phe → Val 
ys → Glu
Yes +ACI (1) CRC/51 52 
36 
High No loss 
N.D. 3 c. 250A>G Yes −ACI (1) CRC/32 High 
S93G 3 c. 277A>G Ser → Gly No +ACI (1) CRC/70 65 N.D. N.D. 
(4) EC/46 
CRC/53 
CA/46 
49 
51 
46 
High 
High 
N.D. 
Loss 
Loss 
N.D. 
c. 467T>G 
V185G 7 c. 554T>G Val → Gly No +ACI (1) CRC/43 44 High Loss 
V213M 8 c. 637G>A Val → Met No −ACI (4) CRC/64 
EC/44 
CRC/67 
CRC/46 
58 
53 
67 
42 
Low 
High 
High 
High 
Loss 
I219V 8 c. 655A>G Ile → Val No .. .. .. .. .. 
S247P 9 c. 739T>C Ser → Pro No −ACI (1) 
+ACI (1) 
CRC/43 
CRC/42 
44 
49 
N.D. 
High 
N.D. 
Loss 
H329P 
del330 
11 c. 986A>C 
990delATC 
His → Pro 
Del Ile 
No 
No +ACI
+ACI (1) 
 (1) 
CRC/32 44 High Loss 
CRC/29 41 High Loss 
CRC/57 62 High Loss 
CRC/45 35 High Loss 
A589D 16 c. 1766C>A Ala → Asp No −ACI (1) CRC/34 34 High Loss 
del612 16 34-1836delT Del Val No +ACI (1) CRC/47 51 N.D. N.D. 
del616 16 . 1846-1848 Del Lys No +ACI (1) CRC/44 50 High Loss 
 
 
 
+ACI (2) 
CRC/43 
CRC/33 
CRC/72 
CRC/69 
CRC/44 
CRC/32 
41 
43 
77 
72 
69 
60 
38 
High 
N.D. 
ow
High 
Low 
MSS 
High 
N.D. 
Loss 
Loss 
K618T 16 c. 1853A>C Lys → Thr No .. .. .. .. .. 
del633–  1897-1989de
(exon 17) 
Del of aa 
633–663 
T
ND .. .. .. .. .. 
Y646C 17 c. 1937A>G yr → Cys Yes −ACI (1) CRC/36 36 High loss
P648L 
P648S 
17 
17 
c. 1943C>T 
c. 1942C>T 
ro → Leu
→ Ser 
Yes 
Yes +ACI 
−ACI (1) 
(1) 
CRC/43 
CRC/54 
43 
50 
High 
High 
loss
Loss 
P654L 17 c. 1961C>T Pro → Leu Yes −ACI (3) 
 
 
CRC/35 
CRC/31 
CRC/38 
CRC/41 
53 
50 
54 
50 
N.D. 
N.D. 
High 
High 
N.D. 
N.D. 
Loss 
Loss 
CRC/35 45 High Loss 
(1) CRC/32 38 High Loss 
CRC/38 38 High N.D. 
V716M 19 c. 2146G>A Val → Met No 
 C/3
CRC/52 
67 
45 
46 
ow
MSS N.D. 
1 vation o  origi id b an a cerev  ind ether t milie  
A am crite  (num milie ncer and th nset f the index patien er
a rs) of can  onset eds.  of mor f dex  availa 6 IHC is
MLH1 protein in the tumor tissue. Aa, amino acid; ACI, Amsterdam criter  I; N.D., mined. 
 
 Conser f the nal amino ac etween hum nd S. isiae. 2 +/− icates wh he fa s fulfil the 
msterd ria I ber of the fa s). 3 The ca  site e age of o (years) o t.  4 Av age 
ge (yea cer  in all affect 5 MSI status the tu rom the in patient, if ble.  analys  of 
ia  not deter
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Figure 7. Schematic representation of the locations of the MLH1 mutations under study in the MLH1 
polypeptide. A) The MLH1 alterations are clustered in the aminoterminus responsible for ATP binding and 
hydrolysis, and in the carboxylterminus, consisting of the PMS2/MLH3/PMS1 interaction domain. B) The 
conservation of the four ATP-binding sites between human MLH1, S. cerevisiae Mlh1 and E. coli MutL, and 
the distribution of the MLH1 mutations around the invariant residues. Sequences were aligned with ClustalX 
software version 1.81 (Thompson et al. 1997). Sequence accession numbers in the NCBI database: human
MLH1, P40692; yeast Mlh1, P38920; bacterial MutL, P2336 (http://www.ncbi.nlm.nih.gov/entrez/). 
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In addition to 31 mutations found in HNPCC families, three MLH1 variations listed in the 
c. 1897-
ing temperatures, and 
loning sites are listed in Table A.1 (see Appendices). All the plasmids used in the present 
udy are listed in detail in Table A.2.  
uman MLH1 cDNA, which was previously cloned into the plasmid pFastBac1 (Invitrogen) 
erase buffer (Promega), 2.5 units of Pfu DNA 
with appropriate restriction enzymes (Table A.1) (Promega), and then ligated into similarly 
international HNPCC mutation database (http://www.insight-group.org/) were studied: (i) c. 
655A>G (I219V), which has been shown to be non-pathogenic in previous functional assays 
(Shimodaira et al. 1998;  Ellison et al. 2001; Trojan et al. 2002; Kondo et al. 2003) and here, 
used as a functional control,  (ii) c. 1853A>C (K618T), whose pathogenicity according to 
previous functional assays has remained partly unsettled (Guerrette et al. 1998; Shimodaira et 
al. 1998; Trojan et al. 2002; Kondo et al. 2003), and (iii) an in-frame deletion 
1989del (del633–663), comprising exon 17, which we previously found to be pathogenic 
(Nyström-Lahti et al. 2002) and here, used as a nonfunctional control. 
 
 
Mutated MLH1 cDNAs and expression vectors 
 
Site-directed mutagenesis and generation of baculoviruses (IIV) 
The MLH1 mutations were generated in human MLH1 cDNA using a PCR-based site-
directed mutagenesis method. The primers, fragment lengths, anneal
c
st
 
H
was used as template. First, two fragments, A and B, were produced in two separate 
amplification reactions (1st PCR in Table A.1), each using a pair of oligonucleotides, where 
the reverse primer for fragment A (primer rA), and the forward primer for fragment B 
(primer fB) carried the nucleotide changes. The first PCR was carried out with 2.5 ng of 
template DNA, 1× Pfu DNA Polym
Polymerase (Promega), 100 pmol of each primer, and 200 µM dNTPs. The PCR products 
were purified, then 15 ng added as template for a second PCR, where the primers fA and rB 
(100 pmol of each) were used to complete the PCR product in the presence of 1× Pfu DNA 
Polymerase buffer (Promega), 2.5 units of Pfu DNA Polymerase (Promega), and 200 µM 
dNTPs. The first and second amplification reactions were carried out in a total volume of 100 
or 50 µl, respectively, for 30 cycles at 94ºC for 1 min, at the specified temperature for 1 min 
(Table A.1), and at 72ºC for 2.5 min. The products of second PCR were purified, digested 
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restricted pFastBac1-MLH1 vector. The recombinant plasmids were amplified in 
electrocompetent E. coli DH5α cells, and finally the mutated MLH1 inserts were verified by 
DNA sequencing. The recombinant baculoviruses were then generated using the Bac-to-Bac 
system according to the manufacturer’s instructions (Fig. 8) (Invitrogen).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Pr
, cDNA of a foreign gene (MLH1 or PMS2) is cloned into the pFastBac1 donor plasmid which is then 
ansformed into electrocompetent E. coli DH10Bac cells (B). These cells contain bacmid DNA with a mini-
tTn7 target site and a helper plasmid. The mini-Tn7 element on the pFastBac1 plasmid can transpose into the 
ini-attTn7 target site in the presence of transposition proteins provided by the helper plasmid. C, DH10Bac 
lonies which contain recombinant bacmids are identified by disruption of a lacZα gene. D, high molecular 
eight bacmid DNA is prepared from selected DH10Bac clones. E, recombinant DNA is then used to transfect 
f9 insect cells using Cellfectin transfection reagent. F, when recombinant viruses are released from the cells, 
ey are collected and used to infect new Sf9 cells for viral amplification or protein production. (Modified from 
oduction of recombinant baculoviruses with the Bac-To-Bac expression system.  
A
tr
at
m
co
w
S
th
Bac-To-Bac Baculovirus Expression System instruction manual; Invitrogen.) 
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Construction of vectors for mammalian expression (IIIV) 
A human expression system was utilized to study the effects of the MLH1 alterations on the 
stability and expression levels of the MutLα variants. For protein production, MLH1and 
PMS2 cDNAs from plasmids pFastBac1-MLH1 (wild-type or mutated) or pFastBac1-PMS2 
(wild-type) were cloned into pEGFP-N1 vector (Clontech) between BamHI and NotI sites, so 
that the EGFP gene was replaced. These constructs are here named as pMLH1-N1 and 
pPMS2-N1, respectively (Table A.2).  
 
Construction of vectors for localization studies (IV) 
MLH1 and PMS2 proteins were fused to fluorescent tags in order to allow studying the 
effects of MLH1 mutations on subcellular localization of MutLα variants. For fluorescent 
protein production, MLH1 and PMS2 were fused to the EGFP gene. For the cloning, the stop 
codons were removed and some new restriction sites were generated in MLH1 and PMS2 
cDNAs by the site-directed mutagenesis method described above at an annealing temperature 
°C, using pFastBac1-MLH1 and pFastBac1-PMS2 as templates. An NheI restriction site 
don with primer pairs 5’-
Sac
GAGCTCTGGTTATTTATG-3’ (fB) and 5’-CTGATTATGATCCTCTAGTAC-3’ (rB). The 
of 45
was generated upstream of the MLH1 start co
CGGATTATTCATACCGTCCC-3’ (fA) and 5’-GAAGAGCCAAGGGCTAGCGTGGCCT-
CG-3’ (rA), and 5’-CGAGGCCACGCTAGCCCTTGGCTCTTC-3’ (fB), and 5’-TTCTCCC 
GTGGCTATGTTG-3’ (rB), for fragments A and B, respectively. A I site was generated 
to replace the MLH1 stop codon using primer pairs 5’-CGGGTGCAGCAGCACATCG-3’ 
(fA) and 5’-CATAAATAACCAGAGCTCACACCTCTC-3’ (rA), and 5’-GAGAGGTGT 
products of the second PCRs were cloned into the pFastBac1-MLH1 vector between BamHI 
and PvuII or NsiI and NotI sites, respectively. In PMS2, the stop codon was replaced and an 
AgeI restriction site generated with primer pairs 5’-GGCTTT GATTTTGTTATCGATG-3’ 
(fA) and 5’-CTACGGTCAGACCGGTGAAATGACAC-3’ (rA), and 5’-GTGTCATTTCAC 
CGGTCTGACCGTAG-3’ (fB) and 5’-GCATGCCTCGAGACTG CAGGCTC-3’ (rB). The 
product of the second PCR was cloned into the pFastBac1-PMS2 vector between restriction 
sites SpeI and NotI. The MLH1 and PMS2 cDNAs without stop codons were then cloned into 
the pEGFP-N1 vector (Clontech) between NheI and SacI and BamHI and AgeI sites, 
respectively. The resulting constructs expressing MLH1-EGFP and PMS2-EGFP fluorescent 
fusion proteins are here termed pMLH1-EGFP and pPMS2-EGFP (Table A.2).  
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 All MLH1 mutation variants from the plasmid pFastBac1-MLH1, except MLH1-P28L, 
MLH1-A29S, MLH1-TSI45-47CF, MLH1-D63E, MLH1-G67R, and MLH1-E71del, were 
cloned into the pMLH1-EGFP vector between the BglII and AccIII sites. The variants 
MLH1-A29S, MLH1-TSI45-47CF, MLH1-D63E, and MLH1-G67R were generated to the 
pMLH1-EGFP plasmid between the NheI And EcoNI sites by site-directed mutagenesis 
described above at an annealing temperature of 45°C. The sequences of inner primers (rA 
and fB) carrying the mutation were same to those in Table A.1, and the sequences of outer 
rimers were: 5’-CGTAACAACTCCGCCCCATTG-3’ (fA) and 5’-GAGCTTGCTCTCGAT 
.3.  
grown in Grace’s Insect Medium (Gibco) in 
e presence of 10% fetal bovine serum, 2 mM L-glutamine, and 50 units/ml of penicillin-
utant and wild-type(WT) MutLα heterodimers, 
7 Sf9 cells were co-infected with MLH1 and PMS2 recombinant 
aculoviruses (Fig. 8). The cells were cultured for 48 hrs.  
p
GTGCTG-3’(rB).  
 
Production of recombinant proteins 
 
Protein production in insect cells (IIV) 
The human MutLα heterodimers containing the mutated MLH1 variants were produced in 
insect cells which allow high expression levels and protein amounts needed for in vitro repair 
and interaction assays. The cell lines used in the study and their specific features are 
presented in Table A
 
Spodoptera frugiperda 9 (Sf9) insect cells were 
th
streptomycin at 27°C. For the production of m
9×105 Sf9 cells were transfected separately using 6 µl of Cellfectin reagent (Invitrogen) with 
5 µl (2.5-5 µg) of bacmid-DNA containing either MLH1 (WT or mutated) or PMS2 insert 
(Fig. 8). The viral stocks were harvested after 72 hrs and then amplified for 120 hrs. For 
protein extraction, 2×10
b
 
Protein production in human cells (IIIV) 
A human expression system was used to study the stability and expression levels of mutated 
MutLα variants. The 293T human embryonic kidney cell line, which lacks MLH1 protein 
because of promoter hypermethylation (Trojan et al. 2001), was grown in Dulbecco’s 
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Modified Eagle Medium/F12 (Gibgo) with 5% fetal bovine serum, 2 mM L-glutamine, and 
50 units/ml of penicillin-streptomycin at 37°C in a 5% CO2 atmosphere. For protein 
production, 3×105 293T cells were seeded in a 35-mm well. After 16 hrs culturing, the cells 
ere co-transfected with 0.5 µg of pMLH1-N1 (WT or mutant) and 0.5 µg of pPMS2-N1 
agent (Roche). After 48 hrs, the cells were 
n the cells were cultured for 24 hrs.  
otal protein extraction from human cells (IIIV) 
ted cells were washed twice with cold 
w
vectors using 3 µl of FuGene6 transfection re
collected by trypsinization.  
 
To study the subcellular localizations of mutated MutLα variants, we expressed MLH1-
EGFP and PMS2-EGFP fluorescent fusion proteins in 293T human cells. Three different 
transfection combinations for each MLH1 variant were performed: 1) each pMLH1-EGFP 
variant was expressed alone, 2) with pPMS2-N1, and 3) each pMLH1-N1 variant was 
expressed with pPMS2-EGFP. The transfection procedure was similar to that above, except 
1×105 293T cells were seeded onto glass coverslips, and cultured for only 4 hrs prior to 
transfection. After transfectio
 
Total protein extraction from insect cells (IIV) 
Total proteins were extracted from Sf9 cells in 200 µl of ice-cold lysis buffer (25 mM Hepes, 
2 mM β-mercaptoethanol, 0.5 mM spermidine, 0.15 mM spermine, 0.5 mM phenylmethyl-
sulfonyl fluoride, 2× Complete protease inhibitor mixture [Roche]) for 30 min. After centri-
fugation at 12,000 g for 50 min at +4°C, the supernatant was collected and NaCl to 100 mM 
and glycerol to 10% were added.   
 
T
For total protein extraction from 293T cells, the collec
PBS. The cells were then lysed in 60 µl of ice-cold extraction buffer (50 mM Tris-Cl pH 8.0, 
350 mM NaCl, 0.5% Nonidet-P40, 1 × Complete protease inhibitor mixture [Roche], 1 mM 
phenylmethylsulfonyl fluoride, 2 µg/ml aprotinin, 0.7 µg/ml pepstatin) for 25 min followed 
by centrifugation at 16,000 g for 3 min at 4°C, after which the supernatant was preserved.  
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Functional analyses 
 
Western blot analysis (IIV) 
The MutLα expression levels in Sf9 insect and 293T human cells were examined by SDS-
PAGE and western blot analysis. Aliquots of  Sf9 total protein extracts (5 and 10 µl) and of 
93T total protein extracts (30 µl) were run on 8% SDS-polyacrylamide gel, and then blotted 
nto a Hybond C membrane (Amersham Pharmacia Biotech) with 30 V for 16 hrs. Non-
sites were blocked with 5% non-fat powdered milk in TBS 
ontaining 0.05% Tween 20 for 1 h. The membrane was then blotted with monoclonal 
µg/ml) (BD Biosciences/PharMingen, clone 168-15) and 
spair was used as a repair substrate in the 
ssay.  
uclear protein extraction 
streptomycin at 37°C in 5% CO2 atmosphere.  
2
o
specific antibody binding 
c
antibodies against MLH1 (0.5 
PMS2 (0.2 µg/ml) (Calbiochem/Oncogene Research, Ab-1). The naturally expressed β-
tubulin protein (anti β-tub: clone 5H1, BD Biosciences/PharMingen) was used as a control to 
compare the expression levels of MutLα variants produced in 293T cells. Horseradish 
peroxidase-linked anti-mouse immunoglobulin was used as a secondary antibody (Amersham 
Pharmacia Biotech). The antibody-bound proteins were visualized by the ECL Western 
blotting analysis system (Amersham Pharmacia Biotech), and the signals were exposed to the 
ECL Hyperfilms (Amersham Pharmacia Biotech). 
 
In vitro MMR assay (IIV) 
 
MMR capacity of the mutated MutLα variants was examined using an in vitro MMR assay. 
For this, nuclear extracts of an MMR-deficient human cell line HCT116 (Table A.3) were 
complemented with the recombinant MutLα variants produced in the Sf9 insect cells. A 
circular DNA heteroduplexes containing a G•T mi
a
 
N
TK6 human lymphoblasts (MMR proficient) and HCT116 human colon carcinoma cells 
(MLH1−/−, MMR deficient) were cultured in RPMI 1640 or McCoy’s medium (Gibco), 
respectively, with 10% fetal bovine serum, 2 mM L-glutamine, and 50 units/ml of penicillin-
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 For preparation of nuclear protein extracts for the in vitro MMR assay, 6×108 cells were 
ollected by trypsinization and centrifuged at 500 g for 10 min at 4°C. The pellet was re-
old isotonic buffer (20 mM Hepes pH 7.9, 5 mM KCl, 1.5 mM 
uffer (isotonic buffer without sucrose). After 
entrifugation at 500 g for 10 min at 4°C, the cells were resuspended in 3 ml of ice-cold 
) was linearized with BanII restriction enzyme. Finally, 680 
g of single-stranded DNA (with T) was annealed with 140 µg of double-stranded linearized 
g circular heteroduplex DNA with a G•T mispair 369 bp 
downstream from a single-strand nick made by BanII, with G on the nicked strand.  
c
suspended in 3.5 ml of ice-c
Mg2Cl, 250 mM sucrose, 0.2 mM phenylmethylsulfonyl fluoride, 1× Complete protease 
inhibitor mixture [Roche], 0.25 µg/ml aprotinin, 0.7 µg/ml pepstatin, 0.5 µg/ml leupeptin, 1 
mM DTT) and centrifuged as above. The supernatant was then removed, and the pellet 
suspended in 3.5 ml of ice-cold hypotonic b
c
isotonic buffer, transferred to a tissue grinder and incubated on ice for 5 min. After 20 strokes 
with a cold pestle, the nuclei were collected by centrifugation at 3,000 g for 10 min at 4°C. 
The pellets were suspended in ice-cold extraction buffer (25 mM Hepes pH 7.5, 10% 
sucrose, 1 mM phenylmethylsulfonyl fluoride, 0.5 mM DTT, 1 µg/ml leupeptine) and NaCl 
up to 155 mM was added. The suspension was rotated for 1 h at 4°C, and then centrifuged 
for 20 min at 14,500 g at 4°C. The supernatant was then dialyzed for 50 min in a Slide-A-
Lyzer 3.5 K dialysis cassette (Pierce) in cold dialysis buffer (25 mM Hepes pH 7.5, 50 mM 
KCl, 0.1 mM EDTA pH 8, 10% sucrose, 1 mM phenylmethylsulfonyl fluoride, 2 mM DTT, 
1 µg/ml leupeptine), after which the buffer was exchanged and the dialysis continued for 50 
min. After centrifugation at 16,000 g for 15 min at  4°C, the supernatant containing the 
nuclear proteins was preserved. 
 
Preparation of DNA heteroduplex 
The circular DNA heteroduplexes containing a G•T mispair and a single-strand nick were 
prepared as reported previously (Lu et al. 1983; Lahue et al. 1989; Holmes et al. 1990). First, 
single-stranded DNA was produced in the E. coli strain XL1 Blue with a helper phage 
M13K07 (New England Biolabs) using pGEM phagemide with a T•A basepair (T on the + 
strand) as a template (Table A.2). Then, double-stranded DNA from pGEM phagemide with 
C•G basepair (C on the + strand
µ
DNA (with C•G basepair), generatin
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Repair assay 
Sf9 total protein extracts estimated to contain equal amounts of recombinant MLH1 (8.0 µg 
of Sf9 extracts for MutLα-WT) were incubated at 37ºC for 30 min, together with 75 µg of 
HCT116 nuclear extract. The reaction was carried out in a total volume of 20 µl, using 100 
ng of DNA heteroduplex as the repair substrate in the presence of 5 mM Mg2Cl, 1 mM 
gluthathione, 50 mg/ml of bovine serum albumin, 0.4 mM dNTPs, and 1.5 mM ATP. The 
total salt concentration of protein extracts used in the reaction was determined, and KCl was 
added so that the final salt concentration was 110 mM. After incubation, the repair reaction 
was stopped by adding 0.7% SDS, 25 mM EDTA and 1.8 µg of Proteinase K. Proteins were 
 phenol-chlorophorm-isoamylalcohol precipitation, and the repaired or non-
m (DAKO).  
as analyzed by direct fluorescence using 
PMS2 proteins were evaluated from over 600 cells in each experiment. Representative 
removed with
repaired DNA was precipitated by a conventional ethanol-precipitation method, and the 
heteroduplex DNA was cut with endonucleases BsaI and BglII. If the repair reaction 
occurred, the G•T mismatch was converted to A•T basepair, and BglII was able to cut the 
DNA duplex. Digested DNA was run in 1% agarose gel with ethidium bromide, and the 
repair efficiency was measured by the cleavage efficiency (the proportion of the amount of 
double-digested DNA to the amount of total DNA). The efficiencies were quantified with 
Image-Pro Version 4.0 (MediaCybernetics). 
 
Detection of fluorescent fusion proteins (IV) 
We expressed the fluorescent MLH1-EGFP and PMS2-EGFP proteins in 293T cells to study 
the effects of MLH1 mutations on the subcellular localization of MutLα. For the detection of 
fluorescent proteins, 24 hours after transfection the 293T cells were washed twice with PBS 
and fixed with 4% paraformaldehyde in PBS for 20 min at room temperature. After fixation, 
the cells were washed with PBS, and the nuclei were stained by incubating cells in PBS with 
300 nM 4’,6’-diamidino-2-phenylindole (DAPI) (Sigma Aldrich) for three min. Slides were 
mounted with Fluorescence Mounting Mediu
 
Intracellular localization of recombinant proteins w
an Axioplan 2 microscope (Carl Zeiss). Each transfection was repeated at least three times, 
and at least 200 cells from each individual transfection were analyzed from randomly 
sampled microscope fields of view. Thus, subcellular localizations of recombinant MLH1 or 
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images were taken with Isis 3.4.3 software (Metasystems) and processed with Adobe 
Photoshop 6.0 (Adobe). The images were representative of at least 90% of the transfected 
cells analyzed.  
 
Combined co-immunoprecipitation and Western blot analysis (IIV) 
 A total of 20 µl of protein A/G agarose suspension (Santa Cruz) was added 
nd incubation was continued for a further 1.5 hrs. The precipitates were centrifuged for five 
an 8% SDS 
The co-immunoprecipitation assay was performed to study the effect of MLH1 mutations on 
MLH1/PMS2 heterodimerization. For the assay, Sf9 (I–IV) or 293T (II) protein extracts 
estimated to contain equal amounts of mutated or WT MLH1 (8.0 µg of Sf9 and 100 µg of 
293T total extracts for MutLα-WT) were incubated for 1 h at 4°C on a rotating wheel with 
0.5 µg of anti-MLH1 antibody (BD Biosciences/PharMingen, clone G168-728) or anti-PMS2 
antibody (BD Biosciences/PharMingen, clone A16-4) in a total volume of 1 ml in RIPA lysis 
buffer (150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM 
Tris-Cl pH 8.0).
a
min at 2,500 g, washed three times with cold RIPA buffer, run on 
polyacrylamide gel, and transferred onto a Hybond C membrane. The interactions between 
MLH1 and PMS2 were detected with Western blot analysis as above. 
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RESULTS 
 
 
Most of the mutations affected the expression or stability of the MLH1 
protein (II-IV) 
 
To determine whether the MLH1 mutations affect the stability of the respective MLH1 
polypeptide, we expressed the protein variants transiently in 293T human embryonic kidney 
cells. This cell line lacks the constitutive MLH1 protein because of hypermethylation of the 
MLH1 promoter, and as a consequence, the PMS2 protein degrades and cannot be detected 
either (Trojan et al. 2002). Thus, also PMS2-WT was also transiently expressed in the cells. 
The MLH1 and PMS2 expression levels were examined in total protein extracts from 293T 
cells with Western blot analysis. Endogenous β-tubulin protein was used as a loading control. 
 
Among the 34 MLH1 mutations, 20 affected either the expression or stability of the encoded 
MLH1 protein so that the quantities of the respective variants were lower than the quantity of 
the MLH1-WT (Table 6). These mutations were: MLH1-P28L, MLH1-TSI45–47CF, MLH1-
D63E, MLH1-G67R, MLH1-del71, MLH1-C77R, MLH1-I107R, MLH1-L155R, MLH1-
V185G, MLH1-S247P, MLH1-H329P, MLH1-del330, MLH1-L550P, MLH1-A589D, MLH1-
del612, MLH1-del616, MLH1-del633–663, MLH1-P648L, MLH1-P648S, and MLH1-P654L. 
As a consequence of low amounts of these MLH1 variants, the amount of PMS2-WT was 
also lower than that expressed with MLH1-WT. The amount of MutLα-del633–663 was 
extremely low, so that both mutant MLH1 and PMS2-WT were barely detectable in the 
protein extract. 
 
The amounts of the MLH1 variants MLH1-A29S, MLH1-F80V, MLH1-K84E, MLH1-
S93G, MLH1-V213M, MLH1-I219V, MLH1-K443Q, MLH1-K618A, MLH1-K618T, 
MLH1-Y646C, MLH1-R659P, MLH1-R659Q, MLH1-A618T, and MLH1-V716M were 
similar to that of the MLH1-WT (Table 6). The amounts of PMS2 expressed with these 
variants were similar to that expressed with MLH1-WT. 
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Table 6. Functional characterization of the MLH1 protein variants under study. Deficiency is 
indicated in gray. Variants are classified as pathogenic (P) or non-pathogenic (N) based on 
the functional results. 
Localization of MLH11 
MLH1 
variant 
 
Expression in 
293T cells 
 
In vitro 
MMR alone with PMS2
Localization of 
PMS2 
with MLH12
 
Interaction 
with PMS2 
 
Variant 
status 
P28L Decreased Deficient n.d.3 n.d. Decreased Normal 4 P 
A29S Normal Normal Normal Normal Normal Normal N 
TSI45-47CF Decreased Deficient Decreased Decreased Decreased Normal P 
D63E Decreased Deficient Decreased Decreased Decreased Normal P 
G67R Decreased Deficient Decreased Decreased Decreased Normal P 
del71 Decreased Deficient n.d. n.d. Decreased Normal P 
C77R Decreased Deficient Decreased Decreased Decreased Normal P 
F80V Normal Deficient Normal Normal Normal Normal P 
K84E Normal Deficient Decreased 5 Normal Normal Normal P 
S93G Normal Normal Normal Normal Normal Normal N 
I107R Decreased Deficient Decreased Decreased Decreased Normal P 
L155R Decreased Deficient Decreased Decreased Decreased Normal P 
V185G Decreased Deficient Decreased Decreased Decreased Normal P 
V213M Normal Normal Normal Normal Normal Normal N 
I219V Normal Normal Normal Normal Normal Normal N 
S247P Decreased Deficient Decreased Decreased Decreased Normal P 
H329P Decreased Normal Decreased Decreased Decreased Normal P 
del330 Decreased Deficient Decreased Decreased Decreased Normal P 
K443Q Normal Normal Normal Normal Normal Normal N 
L550P Decreased Normal Normal Decreased 5 Decreased Normal P 
A589D Decreased Normal Normal Decreased 5 Decreased Normal P 
del 612 Decreased Normal Normal Decreased 5 Decreased Normal P 
del 616 Decreased Normal Normal Decreased 5 Decreased Normal P 
K618A Normal Normal Normal Normal Normal Normal N 
K618T Normal Normal Normal Decreased 5 Decreased Normal P 
del633-663 Decreased Deficient Normal Decreased 5 Decreased Decreased P 
Y646C Normal Normal Normal Normal Normal Normal N 
P648L Decreased Normal Normal Decreased 5 Decreased Normal P 
P648S Decreased Normal Normal Decreased 5 Decreased Normal P 
P654L Decreased Normal Normal Decreased 5 Decreased Normal P 
R659P Normal Deficient Normal Decreased 5 Decreased Decreased P 
R659Q Normal Normal Normal Normal Normal Normal N 
A681T Normal Normal Normal Normal Normal Normal N 
V716M Normal Normal Normal Normal Normal Normal N 
1 The proportion of MLH1-EGFP localized in the nucleus expressed without or with PMS2. 2 The proportion of 
PMS2-EGFP localized in the nucleus when expressed with MLH1. 3 n.d.: not determined. 4 Normal: similar to 
the result received with the MLH1 wild-type. 5 The nuclear proportion of the particular protein variant was only 
slightly reduced when compared to the corresponding result derived from MLH1-WT. 
 
Mismatch repair deficiency was mainly associated with 
aminoterminal MLH1 mutations (I-IV) 
 
The ability of the MLH1 protein variants to complement the MLH1-deficient HCT116 
nuclear extract so that it can repair mismatches were examined in the in vitro MMR assay. In 
complementation, we used Sf9 total extracts including the MutLα variants. Among the 34 
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MLH1 mutations, 15 disrupted the MMR function of the encoded MLH1 protein (Table 6). 
The negative controls (mock and HCT116 without Sf9 extracts), repaired the heteroduplex 
substrate with the efficiencies of 0% and 5% ± 3%, respectively (Fig. 9). The repair 
efficiencies of the two MMR-proficient MutLα variants, 42% ± 6.5% for MutLα-WT and 
37% ± 2% for MutLα-I219V, were used as reference levels. The repair efficiencies of 15 
MutLα variants were lower than the reference levels (Fig. 9). These variants were: MutLα-
P28L, MutLα-TSI45–47CF, MutLα-D63E, MutLα-G67R, MutLα-del71, MutLα-C77R, 
MutLα-F80V, MutLα-K84E, MutLα-I107R, MutLα-L155R, MutLα-V185G, MutLα-
S247P, MutLα-del330, MutLα-del633–663, and MutLα-R659P. The efficiencies of the two 
variants MutLα-H329P and MutLα-del612 were slightly reduced (Fig. 9).  
 
In addition to MutLα-I219V, 16 variants repaired with a similar efficiency to the wild-type 
MutLα (Table 6). These variants were: MutLα-A29S, MutLα-S93G, MutLα-V213M, 
MutLα-K443Q, MutLα-L550P, MutLα-A589D, MutLα-del616, MutLα-K618A, MutLα-
K618T, MutLα-Y646C, MutLα-P648L, MutLα-P648S, MutLα-P654L, MutLα-R659Q, 
MutLα-A618T, and MutLα-V716M.  
 
Since most of the MLH1 variants were shown to be unstable but still functional in the in vitro 
MMR assay, we also wanted to find out whether the possible minor functional defects of the 
protein variants were actually compensated by the high protein quantity used in the assay. 
This was done by titrating the Sf9/MutLα protein amounts. First, we used MLH1-del616 and 
showed that when the protein amounts were 1/10 of those originally used, no reduction in the 
repair ability were detected with either MutLα-WT or MutLα-del616 (II). When the amounts 
were 1/20 of the original amounts, the repair efficiency of MutLα-WT was decreased slightly 
(from 33% ± 2.9%  to 29% ± 3.1%), while the repair efficiency of MutLα-del616 was 
decreased from 31% ± 3.7%  to 7% ± 3.1%. The titration experiment was also performed 
with MutLα-K443Q, MutLα-Y646C, MutLα-P648S, and MutLα-V716M, whose repair 
efficiencies, however, were not different from MutLα-WT (unpublished data).  
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Figure 9. Mismatch repair efficiency of HCT116 nuclear extract (MLH1–/–) complemented with MutLα 
variants produced in Sf9 cells. Mock contains only heteroduplex DNA without any proteins, HCT116 is a 
negative control. The repair efficiencies are indicated as percentages, and were as follows: Mock 0%; HCT116 
alone, 5% ± 3%; MutLα-WT, 42% ± 6.5%; MutLα-P28L, 2% ± 1%; MutLα-A29S, 45% ± 10%; MutLα-
TSI45-47CF, 2% ± 1%; MutLα-D63E, 8% ± 5%; MutLα-G67R, 1% ± 1%; MutLα-E71del, 3.5% ± 3%; 
MutLα-C77R, 1% ± 1%; MutLα-F80V, 6% ± 5%; MutLα-K84E, 1% ± 1%; MutLα-S93G, 58% ± 3%; MutLα-
I107R, 1% ± 1%; MutLα-L155R, 7% ± 7%; MutLα-V185G, 8% ± 5%; MutLα-V213M, 39% ± 2.5%; MutLα-
I219V, 37% ± 2%; MutLα-S247P, 17% ± 8%; MutLα-H329P, 30% ± 13%; MutLα-I330del, 10% ± 10%; 
MutLα-K443Q, 48% ± 12%; MutLα-L550P, 40.5% ± 2.5%; MutLα-A589D, 41.5% ± 3.5%; MutLα-V612del, 
32% ± 2%; MutLα-K616del, 35% ± 4%; MutLα-K618A, 43.5% ± 7.5%; MutLα-K618T, 45.5% ± 8.5%; 
MutLα-Y646C, 47% ± 7%; MutLα-P648L, 43% ± 2%; MutLα-P648S, 53% ± 7%; MutLα-P654L, 46.5% ± 
6.5%; MutLα-R659P, 19.5% ± 9%; MutLα-R659Q, 36% ± 3%; MutLα-A681T, 48.5% ± 6.5%; MutLα-
V716M, 46% ± 7.5%, MutLα-del633-663, 1% ± 1%. The data are presented as the average of 3–10 independent 
experiments ± SD. 
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The unstable MLH1 variants affected subcellular localization of 
MutLα (IV) 
 
To study the subcellular localization of the MLH1 variants we first fused the MLH1 and 
PMS2 cDNAs with cDNA of the EGFP gene and then transiently expressed the fluorescent 
protein variants in 293T human cells.  
 
In transfection, we used three combinations of vectors: (i) the pMLH1-EGFP variant alone, 
(ii) the pMLH1-EGFP variant together with pPMS2-N1, and (iii) pPMS2-EGFP with each 
pMLH1-N1 variant. Thus, we were able to study (i) the location of MLH1 alone; (ii) the 
location of MLH1 when PMS2 was present; and (iii) the location of PMS2 expressed with 
the respective MLH1 variant. The study situation was similar in (ii) and (iii), except a 
different protein was fluorescent.  
 
When expressed without PMS2, the wild-type MLH1 protein was detected almost completely 
in the nucleus, and when PMS2 was added, a very small cytoplasmic proportion of the 
MLH1-EGFP protein seen when PMS2 was not present was also imported into the nucleus. 
In contrast, when expressed without MLH1, PMS2-EGFP was located mainly in the 
cytoplasm, and the intensity of fluorescence was lower than that of MLH1-EGFP. When 
expressed with MLH1, PMS2-EGFP was mainly nuclear with increased intensity of 
fluorescence.  
 
Altogether, the MLH1 variants which affected the subcellular localization of either MLH1 or 
PMS2 in our localization study can be divided into two cathegories. The first group includes 
the MLH1 variants i) which were located mostly in the cytoplasm when expressed without 
PMS2, ii) the nuclear proportion was only slightly increased when PMS2 was added, and iii), 
PMS2 was also mainly cytoplasmic when expressed with these MLH1 variants. The first 
group consists of the aminoterminal variants MLH1-TSI45–47CF, MLH1-D63E, MLH1-
G67R, MLH1-C77R, MLH1-I107R, MLH1-L155R, MLH1-V185G, MLH1-S247P, MLH1-
H329P, and MLH1-del330 (Table 6). The second group includes the MLH1 variants i) which 
were almost completely nuclear, like the wild-type MLH1 when expressed alone, ii) the 
nuclear proportion was not increased when PMS2 was present, and iii) PMS2-EGFP 
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remained mainly cytoplasmic when expressed with these MLH1 variants. The second group 
consists of the carboxylterminal variants MLH1-L550P, MLH1-A589D, MLH1-del612, 
MLH1-del616, MLH1-K618T, MLH1-del633–663, MLH1-P648L, MLH1-P648S, MLH1-
P654L, and MLH1-R659P (Table 6).   
 
The nuclear localization of the variant MLH1-K84E was only slightly reduced without 
PMS2. The subcellular localization of the variants MLH1-P28L and MLH1-del71 could not 
be determined because of problems in the cloning phase. However, PMS2-EGFP was mainly 
cytoplasmic when expressed with either of the two MLH1 variants. The variants MLH1-
A29S, MLH1-F80V, MLH1-S93G, MLH1-V213M, MLH1-I219V, MLH1-K443Q, MLH1-
K618A, MLH1-Y646C, MLH1-R659Q, MLH1-A681T, and MLH1-V716M were similar to 
MLH1-WT in the localization study (Table 6).  
 
Most MLH1 variants interacted with PMS2  in the co -
immunoprecipitation assay (I-IV) 
 
The co-immunoprecipitation assay was performed to study the effect of MLH1 mutations on 
MLH1/PMS2 heterodimerization. The analysis was performed using Sf9 total extracts with 
overexpressed MLH1 variants and PMS2-WT. The protein extracts were incubated with 
agarose beads covered with antibodies against either MLH1 or PMS2. The precipitants were 
then detected with Western blot analysis. In study II, we also used total extracts of the 293T 
cells to investigate the interactions of MLH1-WT and MLH1-del616 with PMS2.  
 
Generally, the MLH1/PMS2 interaction was not inhibited (Table 6). Only the variants 
MLH1-del633-663 and MLH1-R659P were defective in the MLH1/PMS2 interaction, so that 
PMS2 could not be co-precipitated with either of these two variants (Table 6). 
 
Genotype and phenotype correlations (I-IV) 
 
We aimed to find genotype-phenotype correlations by comparing the results of functional 
studies with clinical data obtained from the families under study. Based on the results of our 
functional analysis, the MLH1 variants were interpreted as pathogenic or non-pathogenic. 
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The interpretations were collected to Table 7 together with clinical characteristics of patients 
and their families.  
 
Thirty-one of the MLH1 alterations under study were found in 52 different families. Thirty-
one of these families carry alterations which were pathogenic in our assays, and 21 families 
carry non-pathogenic alterations (Table 7). The index patient was diagnosed for CRC or EC 
before the age of 50 in 28/31 families (90%) which carry pathogenic MLH1 alterations. In 
three cases the age was over 50 years (Table 7). Among the families carrying non-pathogenic 
variants, 12/21 (57%) index patients were diagnosed before the age of 50. In nine cases 
(43%) the index patient was over 50 years of age at the time of cancer diagnosis.  
 
In 75% (39/52) of all the families, the average age of cancer onset was < 55 years (Table 7). 
The average includes all affecteds, not only mutation carriers. Among the families carrying 
pathogenic MLH1 mutations, the average age was < 55 years in all families. In one case, the 
index patient was the only affected one and the average was not determined. Among the 
cases with non-pathogenic alterations, the average were determined in 16 cases. In five cases, 
the index patient was the only affected. The average was < 55 years in 9/16 cases, and over 
55 in 7/16 cases. 
 
A total of 44 tumors were analysed for MSI and as a result, 38 tumors were reported to have 
a high MSI status (Table 7). Sixty-six % of them (25) were found in families carrying 
pathogenic MLH1 mutations. All the tumors reported to have low or no MSI were occurred 
in the families carrying non-pathogenic MLH1 alterations.   
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Table 7. Phenotypic characteristics of the patients and their families carrying the MLH1 
alterations under study, and the result of functional interpretation of the corresponding 
MLH1 variant. 
MLH1  
variant 
No. of 
Patients1
Index 
Patient 2
Average age 
of onset 3
 
MSI4
Functional 
interpretation 
Additional MLH1 
mutations? 5
P28L 4 CRC/30 37 High Pathogenic Not found 
P28L 2 CRC/27 29 High Pathogenic Not found 
A29S 4 CRC/37 47 High Non-pathogenic MLH1, g. –27C>A 
TSI45–47CF 4 CRC/32 43 N.D. Pathogenic Not found 
D63E 3 CRC/44 41 High Pathogenic Not found 
G67R 1 CRC/36 N.D. 6 High Pathogenic Not found 
del71 8 CRC/24 27 High Pathogenic Not found 
del71 9 CRC/19 36 High Pathogenic Not found 
C77R 10 CRC/22 32 High Pathogenic Not found 
F80V 3 CRC/51 52 High Pathogenic Not found 
K84E 2 CRC/32 36 High Pathogenic Not found 
S93G 13 CRC/70 65 N.D. Non-pathogenic Not found 
I107R 7 EC/46 49 High Pathogenic Not found 
I107R 7 CRC/53 51 High Pathogenic Not found 
I107R 7 CA/46 46 N.D. Pathogenic Not found 
I107R 4 CRC/30 54 High Pathogenic Not found 
L155R 5 CRC/33 41 High Pathogenic Not found 
V185G 8 CRC/43 44 High Pathogenic Not found 
V213M 3 CRC/64 58 Low Non-pathogenic Not found 
V213M 4 EC/44 53 High Non-pathogenic Not found 
V213M 1 CRC/67 N.D. High Non-pathogenic Not found 
V213M 2 CRC/46 42 High Non-pathogenic Not found 
S247P 10 CRC/43 44 N.D. Pathogenic Not found 
S247P 4 CRC/42 49 High Pathogenic Not found 
H329P 8 CRC/32 44 High Pathogenic Not found 
del330 6 CRC/29 41 High Pathogenic Not found 
K443Q 8 CRC/57 62 High Non-pathogenic Not found 
L550P 3 CRC/45 35 High Pathogenic Not found 
A589D 3 CRC/34 34 High Pathogenic Not found 
del612 5 CRC/47 51 N.D. Pathogenic Not found 
del616 12 CRC/44 50 High Pathogenic Not found 
K618A 2 CRC/43 41 High Non-pathogenic Not found 
K618A 5 CRC/33 43 N.D. Non-pathogenic Not found 
K618A 3 CRC/76 77 Low Non-pathogenic Not found 
K618A 2 CRC/72 72 High Non-pathogenic Not found 
K618A 1 CRC/69 N.D. Low Non-pathogenic Not found 
K618A 1 CRC/44 N.D. MSS Non-pathogenic Not found 
K618A 10 CRC/32 38 High Non-pathogenic  MLH1, c. 1976G>A (R659Q) 
Y646C 1 CRC/36 N.D. High Non-pathogenic Not found 
P648L 4 CRC/43 43 High Pathogenic Not found 
P648S 11 CRC/54 50 High Pathogenic Not found 
P654L 3 CRC/35 53 N.D. Pathogenic Not found 
P654L 6 CRC/31 50 N.D. Pathogenic Not found 
P654L 7 CRC/38 54 High Pathogenic Not found 
P654L 2 CRC/41 50 High Pathogenic Not found 
R659P 7 CRC/35 45 High Pathogenic Not found 
R659Q 10 CRC/32 38 High Non-pathogenic Not found 
A681T 1 CRC/38 N.D. High Non-pathogenic Not found 
V716M 3 CRC/65 67 Low Non-pathogenic Not found 
V716M 6 EC/39 45 High Non-pathogenic Not found 
V716M 2 CRC/43 57 High Non-pathogenic Not found 
V716M 12 CRC/52 46 MSS Non-pathogenic Not found 
1 Number of affected patients with HNPCC tumors. 2 The type of tumor and the age of onset (years) of the index 
patient. Ages < 50 years are indicated in gray. 3 Average age of cancer onset in all affecteds in the family. 
Averages  < 55 years are indicated in gray. 4 MSI status of the tumor from the index patient. High statuses are 
indicated in gray. 5 Possible additional MMR gene mutations found in the family are indicated in gray. 6 
Average ages were not determined, if the index patient is the only affected. N.D., not determined. 
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 DISCUSSION 
 
 
One of the central problems in the diagnosis of HNPCC is the interpretation of missense 
mutations. Furthermore, the variety of clinical phenotypes of putative HNPCC kindreds 
interferes with diagnostics, counselling and design of appropriate follow-up and treatment 
strategies. The biological tools to predict the pathogenicity of the different mutations would 
be of prime clinical importance. 
 
The present study attempted to determine the pathogenicity of nontruncating MLH1 germline 
alterations found in putative HNPCC patients. Furthermore, we wanted to characterize how 
these alterations affect the MLH1 protein and cause the pathogenicity. Generally, mutations 
can be pathogenic in four basic ways affecting the quality or quantity of the encoded protein, 
or the location or timing of its production. Some mutations may affect the protein in more 
than one of these ways.  
 
Here, the functional significance of 34 minor MLH1 alterations was elucidated by 
characterizing the stability/expression, MMR capability, and subcellular localization of the 
mutated protein variants. The results suggested that 24 of the 34 alterations were pathogenic, 
while 10 were non-pathogenic.  
 
Minor aminoterminal MLH1 mutations cause protein instability and 
defective mismatch repair (I, IV)  
 
Most of the variants which carry mutations in the aminoterminal half of the MLH1 
polypeptide (in codons 28–330) were both unstable when expressed in human cells and 
defective in MMR. This group includes the variants MLH1-P28L, MLH1-TSI45–47CF, 
MLH1-D63E, MLH1-G67R, MLH1-del71, MLH1-C77R, MLH1-I107R, MLH1-L155R, 
MLH1-V185G, MLH1-S247P, and MLH1-del330. MLH1-F80V and MLH1-K84E were 
defective in MMR but still stable. The average repair efficiencies of the deficient variants 
varied between 1% and 10% excluding MLH1-S247P, whose repair efficiency (17%) was 
higher but still lower than that of the WT protein (42%). In contrast, the repair efficiency of 
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the variant MLH1-H329P, in which the mutation is located in the middle of the polypeptide, 
was as high as 30%, indicating its repair proficiency.  
 
The results derived from our expression and repair assays are consistent with the current 
knowledge of the structure and function of the MLH1 protein. The aminoterminal MLH1 
mutations are unlikely to affect the interaction between MLH1 and PMS2, because the 
interaction region in MLH1 is carboxylterminal (Guerrette et al. 1999; Kondo et al. 2001). 
Instead, the mutations in the aminoterminal part of the MLH1 polypeptide most likely disrupt 
the binding and/or hydrolysis of the ATP molecule. Four aminoterminal motifs in MLH1 
have been shown to be responsible for ATP binding/hydrolysis and are highly conserved 
between the members of GHKL ATPase superfamily (Bergerat et al. 1997; Mushegian et al. 
1997; Dutta and Inouye 2000). Furthermore, the binding and hydrolysis of ATP is shown to 
be critical for stability and function of MutLα (Ban et al. 1999; Tran and Liskay 2000; 
Räschle et al. 2002). Consistent with this, the pathogenicity of 11 aminoterminal MLH1 
mutations associated with both malfunction and low amount of the encoded protein.   
 
Some of the aminoterminal MLH1 mutations probably directly affect ATP binding and 
hydrolysis, while the others alter the protein structure around the ATP-binding site. The 
variant MLH1-D63E is interesting. Substitution of D63 has been previously shown to 
dramatically reduce the expression of MutLα (Räschle et al. 2002), consistent with the fact 
that the aspartic acid 63 (58 in E. coli) lies in the bottom of the ATP-binding pocket of MutL 
and forms a direct hydrogen bond with the exocyclic aminogroup of the adenine base (Ban et 
al. 1999). Analogously, in the present study, the expressed amount of MLH1-D63E was 
lower than the amount of MLH1-WT both in Sf9 and 293T cells.  
 
Evidence for the instability of the MLH1 variants carrying aminoterminal mutations was also 
provided by detection of decreased amounts present in the nucleus, most likely caused by 
degradation of the variants already in the cytoplasm. As a consequence, PMS2 degrades as 
well. PMS2 is frequently reported to be unstable in the absence of MLH1, or more 
specifically, ATP-binding by MLH1 (Tran and Liskay 2000; Räschle et al. 2002). The 
subcellular localization of two variants, MLH1-P28L and MLH1-del71, could not be 
determined because of the problems in the cloning phase. However, in the co-transfections, 
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PMS2-EGFP localized similarly with these two variants as with the other variants, which 
were unstable in the human expression system and defective in in vitro MMR. In the context 
of ATP binding/hydrolysis, the mechanisms of pathogenicity of MLH1-F80V and MLH1-
K84E are different from the other aminoterminal mutations because they caused only 
defective MMR, not protein instability. 
 
MLH1-K84E may interfere with the nuclear import of MLH1 (IV)  
 
MLH1-K84E was the only protein variant included in the study which was stable in 293T 
cells, but, without PMS2, its nuclear proportion was reduced when compared to the 
corresponding result derived from MLH1-WT. When PMS2 was present, the nuclear 
proportions of MLH1-K84E and MLH1-WT were similar. This result suggests that the 
substitution of a lysine by a glutamatic acid at position 84 affects the nuclear import of 
MLH1. In the co-expression with PMS2 the variant was imported normally into the nucleus, 
most probably by assistance of a functional nuclear localization signal (NLS) in PMS2, 
which has been shown to import the whole MutLα into the nucleus (Wu et al. 2003). 
 
A recent study performed with mouse protein homologues suggested that PMS2 expressed 
alone does not reside in the nucleus because of impaired nuclear import, and that the 
dimerization of MLH1 and PMS2 is essential for the nuclear import of MutLα (Wu et al. 
2003). Furthermore, another study showed that MLH1 resides in the nucleus independently 
of PMS2, whereas nuclear localization of PMS2 requires MLH1 (Luo et al. 2004). Consistent 
with that, our unpublished studies with the human MLH1 and PMS2 proteins have shown 
that the formation of MutLα is essential for nuclear transport of PMS2 but not of MLH1 
(Raevaara et al., unpublished data). 
 
The NLS of human and mouse MLH1 is suggested to consist of the residues PRKRHK. This 
represents a "classical" NLS, originally identified in the simian virus SV40 large T antigen 
(Kalderon et al. 1984). In our unpublished studies, the MLH1 polypeptide was shown to have 
an NLS at codons 468–473, consistent with the NLS in the mouse Mlh1 at the similar 
postition (Wu et al. 2003). However, the results of the present study suggest that residue 84 
may have a role in the nuclear targeting of MLH1.  
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Pathogenicity of minor carboxylterminal MLH1 mutations is mainly 
associated with protein instability (IIIV) 
 
In addition to the 11 aminoterminal mutations, which caused protein instability, eight 
variants with carboxylterminal mutations were also unstable when expressed in the 293T 
cells. Here, the instability is most probably associated with structural changes in the 
polypeptide, not with the defective ATP binding/hydrolysis. The different cause of the 
instability between the aminoterminal and carboxylterminal variants is supported by the 
finding that carboxylterminal variants showed instability only when extracted from the 293T 
cells and detected with Western blot analysis. When they were fused with EGFP and detected 
by fluorescence in situ they were as stable as the wild-type MLH1.  
 
Remarkably, among the carboxylterminal mutations (between the codons 443 and 716), only 
MLH1-del633–663 and MLH1-R659P affected the mismatch repair function in vitro. Their 
pathogenicity is associated with deficient interaction between MLH1 and PMS2, verified in 
the co-immunoprecipitation assay. Furthermore, the repair efficiency of the variant MLH1-
del612 was slightly reduced (32%), but still classified as normal. The PMS2 interaction motif 
in the MLH1 polypeptide is mapped to the amino acids 492–743 or 506–743 (Guerrette et al. 
1999; Kondo et al. 2001). Accordingly, the pathogenicity of carboxylterminal MLH1 
mutations are often proposed to be associated with the defective interaction with PMS2 
(Guerrette et al. 1999; Brieger et al. 2002). However, previous studies have shown that all 
amino acid substitutions in the interaction region do not prevent the interaction (Ellison et al. 
2001; Kondo et al. 2003).  
 
Eight carboxylterminal variants, MLH1-L550P, MLH1-A589D, MLH1-del612, MLH1-
del616, MLH1-K618T, MLH1-P648L, MLH1-P648S, and MLH1-P654L were proficient in 
the in vitro MMR assay and showed interaction with PMS2. Furthermore, when fused with 
EGFP, they were detected in the nucleus at similar levels as MLH1-WT. However, PMS2-
EGFP was still highly cytoplasmic when expressed with these MLH1 variants. Because 
PMS2 is not imported into the nucleus without MLH1, the results may suggest problems in 
their heterodimerization, which were undetectable in the co-immunoprecipitation assay.  
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The previous results of the functionality and stability of MLH1-K618T are controversial 
(Shimodaira et al. 1998; Guerrette et al. 1999; Brieger et al. 2002; Trojan et al. 2002; Kondo 
et al. 2003). Based on our functional results, MLH1-K618T may slightly affect the MutLα 
formation, but does not inhibit it totally. When the protein amount was adequate, it was 
repair-proficient in the MMR assay.  
 
In study II, we repeated the in vitro MMR assay and reduced the MutLα protein amounts 
used. By lowering the optimal amount of the protein the repair efficiency of MLH1-del616 
decreased much quicker than that of MLH1-WT, suggesting that the amount of protein is 
critical to the repair function of MLH1-del616. This variant was previously shown to be 
pathogenic, but its pathogenicity was suggested to be associated with defective formation of 
MutLα (Shimodaira et al. 1998; Guerrette et al. 1999), whereas in our study MLH1-del616 
was unstable but still able to repair mismatches, suggesting that its pathogenicity is linked to 
shortage of the functional protein. 
 
Minor deletions and proline substitutions cause instability of MLH1 
(III, IV) 
 
It is noteworthy that all deletions (MLH1-TSI45–47CF, MLH1-del71, MLH1-del330, 
MLH1-del612, MLH1-del616, and MLH1-del633–663) independent of their location in 
MLH1, caused protein instability in the human expression system. Especially the amount of 
MLH1-del633–663 was nearly undetectable in the Western blot analysis. 
 
Furthermore, excluding MLH1-R659P, all mutations (MLH1-P28L, MLH1-S247P, MLH1-
H329P, MLH1-L550P, MLH1-P648L, MLH1-P648S, MLH1-P654L) which lead to proline 
substitutions caused protein instability. This phenomenon may be explained by the structure 
of proline, which has an important role in protein folding (Eyles and Gierasch 2000). The 
rigidity of the ring side-chain makes the folding of proline residues in protein structures 
difficult. Proline often plays a role in turns of polypeptide chains, and also as a breaker of α 
helices. Because of these unique characters, proline substitutions may seriously affect protein 
structures (Eyles and Gierasch 2000). 
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No support for pathogenicity of 9 MLH1 alterations found in putative 
HNPCC families (IV) 
 
We found no support for pathogenicity of protein variants MLH1-A29S, MLH1-S93G, 
MLH1-V213M, MLH1-K443Q, MLH1-K618A, MLH1-Y646C, MLH1-R659Q, MLH1-
A681T, and MLH1-V716M. Additionally, the variant MLH1-I219V, which is classified as 
polymorphism and has been shown to be non-pathogenic in previous functional assays 
(http://www.InSiGHT-group.org; Shimodaira et al. 1998; Ellison et al. 2001; Trojan et al. 
2002; Kondo et al. 2003), was also totally proficient in all our assays. MLH1-S93G and 
MLH1-V213M are also classified as non-pathogenic based on previous functional results 
(Ellison et al. 2001; Nyström-Lahti et al. 2002: Kondo et al. 2003), which is consistent with 
the results of the present study.  
 
In some cases, the cancer susceptibility has been later shown to be associated with another 
MLH1 mutation. In the family carrying MLH1-A29S, another MLH1 mutation (g. –27C>A) 
was found to segregate with the disease. This mutation affects the untranslated region and its 
pathogenicity should be characterized by RNA-based methods.  
 
Furthermore, the family, which showed the most severe HNPCC phenotype among MLH1-
K618A-carrying families in the present study, carries also another MLH1 mutation, c. 
1976G>A (R659Q). Both of the resulting MLH1 protein variants, K618A and R659Q, were 
non-pathogenic in our functional assays.  
 
Remarkably, three previously described MLH1 alterations, a nonsense mutation c. 1975C>T 
(R659X) and missense mutations c. 1976G>C (predicted coding change R659P) and c. 
1976G>T (R659L), which affect the same codon as c. 1976G>A (R659Q), have been 
reported to lead to an aberrant skipping of exon 17 (Nyström-Lahti et al. 1999). Nonsense, 
missense, and even translationally silent mutations can affect resulting gene products by 
inducing the splicing machinery to skip the mutant exons (Cartegni et al. 2002). Apparently, 
these mutations in MLH1 codon 659 alter cis-elements, for example exonic splicing 
enhancers (ESEs) that are important for correct splicing (Cartegni et al. 2002). The resulting 
protein variant MLH1-del633–663 is both MMR-deficient and unstable (Nyström-Lahti et al. 
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2002 and present study). We suggest that MLH1 mutation c. 1976G>A may also lead to 
aberrant splicing of exon 17, as do all other published one-nucleotide mutations affecting 
codon 659, and may be the susceptibility allele in the family carrying two MLH1 alterations. 
Remarkably, our cDNA-based experiments can not be used to detect splicing defects. 
Possible aberrant splicing should be verified from RNA derived from the patients carrying 
these germline mutations.  
 
MLH1-K618A affects a repeat of three lysine residues, located at codons 616–618 of the 
MLH1 polypeptide. Two other MLH1 mutations, MLH1-del616 and MLH1-K618T, affect 
the same region. However, it has been shown that different mutations even in the same codon 
can cause either complete elimination of MMR function or have little-to-no effect on protein 
function (Ellison et al. 2001). Consistent with this, the protein variant MLH1-K618A acted 
similarly to WT MLH1 in all our assays, while MLH1-K618T had problems in the 
localization assay, and MLH1-del616 had problems both in stability and localization. MLH1-
K618A is classified both as pathogenic and non-pathogenic in the InSiGHT database 
(http://www.insight-group.org/). It has shown pathogenicity in a functional study, in which it 
has been suggested to affect the interaction between MLH1 and PMS2 (Guerrette et al. 
1999). In another study, it was suggested to be non-pathogenic or affect only slightly the 
interaction between MLH1 and PMS2 (Kondo et al. 2003).  
  
Basic criteria in support of pathogenicity of a missense alteration include evolutionary 
conservation of  the original residue and an amino acid change of a nonconservative nature. 
Four of the 10 MLH1 alterations which acted similar to WT in our assays affect amino acids, 
which are conserved between human and yeast S. cerevisiae. These residues are K443, Y646, 
R659, and A681. The other six affect nonconserved amino acids. Seven of the 10 alterations 
(MLH1-A29S, MLH1-S93G, MLH1-K443Q, MLH1-K618A, MLH1-Y646C, MLH1-R659Q, 
and MLH1-A681T) lead to nonconservative substitutions, which change the polarity of the 
residue in question.  
 
To further estimate the significance of the MLH1 variants under study, our collaborators 
constructed multiple sequence alignments of human MLH1 with 20 other eukaryotic species 
using ClustalW software (Thompson et al. 1994) (IV). The SIFT (Sorting Intolerant From 
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Tolerant) program was used to predict the outcome of all missense variants (deletions were 
excluded) (Ng and Henikoff 2001). SIFT classifies each amino acid substitution as tolerated 
or deleterious. SIFT correctly predicted the functional results for 23 out of 28 variants (IV). 
Eight out of 10 functionally non-pathogenic variants were predicted as tolerated (A29S, 
S93G, V213M, I219V, K443Q, K618A, R659P, V716M). Y646C and A681T were predicted 
as deleterious. Statistically valid conclusions based on sequence homology are usually 
limited by insufficient sample size of tested variants, insufficient size of sequence databases, 
insufficient epidemiological data, or lack of reliable functional assays (Cooper et al. 2003; 
Greenblatt et al. 2003; Fleming et al. 2003; Mooney et al. 2003; Goldgar et al. 2004). The 
present study addresses all of these limitations.  
 
MLH1 alterations with multiple, mild, or no defects in functional 
assays are linked to distinct clinical phenotypes (I-IV) 
 
By comparing the genetic and biochemical data derived from the functional assays with the 
clinical data, we aimed to find genotype-phenotype correlations in the studied families. 
Altogether, 22 of 34 mutations were shown to be pathogenic in more than one assay (Table 
6). These multidefective MLH1 mutations are all associated with early age of cancer onset 
and high MSI phenotype in the tumors (Table 7).  
 
Two mutations, MLH1-F80V and MLH1-K618T, interfered only with a single protein 
function in our assays. MLH1-F80V caused MMR defect but no protein instability or 
dislocation. Consistent with this, MLH1-F80V caused high MSI phenotype but the MLH1 
protein was still present in the tumor (Table 5). The variant MLH1-K618T affected the 
nuclear localization of PMS2, but acted otherwise normally.  
 
Many families that carry one of the variants whose pathogenicity remained obscure are 
associated with nontypical or mild features of HNPCC. The variant MLH1-S93G was found 
in a family in which the mean age of cancer onset was notably high (65 years), when it 
normally is < 50 years (Lynch et al. 1993). The variant MLH1-V213M was found in four 
families which do not fulfill the Amsterdam criteria (Table 5) (Vasen et al. 1991, 1999). 
MLH1-K443Q was found in one family which does not fulfill the Amsterdam criteria, and in 
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which the mean age of cancer onset was relatively high (62 years). MLH1-K618A is one of 
the germline MMR gene mutations which are found worldwide (Peltomäki and Vasen 2004). 
The present study includes 7 families with the MLH1-K618A alteration. In these families, the 
mean ages of onset varying between 38 and 77, MSI phenotypes were of high, low or no 
instability, and IHC analyses revealed loss or no loss of MLH1 in the tumors. MLH1-Y646C 
was found only in one individual with CRC, and IHC analysis revealed no loss of MLH1 
protein in the tumor tissue. Also MLH1-A681T was found only in one affected individual. 
MLH1-V716M was found in four families in which the mean age of cancer onsets varied 
between 45 and 67. The MSI phenotypes of tumor tissues were of high, low or no instability, 
and the IHC analysis revealed loss or no loss of MLH1 protein.  
 
As a conclusion, the MLH1 variants which remained non-pathogenic in our functional 
assays, are likely to be harmless variants or cause in vivo a slight effect which is undetectable 
by the methods used in the present study. This is supported by the mild or atypical HNPCC 
characteristics of the families carrying these gene variants, and by the comparative sequence 
analysis. On the other hand, there are families carrying these non-pathogenic MLH1 
alterations, but which show typical HNPCC characteristics including highly MSI-positive 
tumors and early ages at cancer onset. These families should be examined to evaluate 
possible further MMR gene mutations.  
 
MLH1-P648S homozygosity is associated with mild features of 
neurofibromatosis type I (III) 
 
The individuals who are homozygous for an MMR gene mutation or carry germline 
mutations in both alleles of an MMR gene have usually hematological malignancies and 
features of de novo neurofibromatosis type 1 syndrome (NF1) such as café-au-lait spots, 
axillary freckles, and neurofibromas (Table 2) (Ricciardone et al. 1999; Wang et al. 1999; De 
Rosa et al. 2000; Trimbath et al. 2001; Vilkki et al. 2001; Whiteside et al. 2002; Bougeard et 
al. 2003; De Vos et al. 2004; Gallinger et al. 2004; Menko et al. 2004). 
 
The mutation MLH1-P648S has been previously found in a Danish HNPCC family with 10 
colorectal cancer patients (Bisgaard et al. 2002). A 6-year-old child conceived from a 
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consanguineous mating between first cousins and homozygous for the mutation displayed 
café-au-lait spots and a skin tumor clinically diagnosed as a neurofibroma, but no other 
abnormalities. The mutation cosegregated with disease phenotype in the family, and was 
associated with the typical HNPCC phenotype including excess of colorectal cancers in 
affected individuals, average age of onset at 50 years, high MSI and lack of MLH1 protein in 
the tumor tissues.  
 
To date, four HNPCC families with individuals carrying homozygous germline MLH1 
mutations have been described (Ricciardone et al. 1999; Wang et al. 1999; Vilkki et al. 2001; 
Gallinger et al. 2004). The children, who carried a homozygous MLH1 mutation R226X, 
were diagnosed with NF1 (Ricciardone et al. 1999). One of the patients developed atypical 
chronic myeloid leukemia at 12 months, the other developed non-Hodgkin’s lymphoma at 39 
months, and the third child has an acute leukemia diagnosed at the age of 24 months (Table 
2). In the second reported case, two sisters carried a homozygous MLH1 mutation G67W 
(Wang et al. 1999) and had the clinical features of NF1. One of the children died at the age 
of 2 of non-Hodgkin’s lymphoma, and the other was diagnosed with acute myeloid leukemia 
at age 6, and with medulloblastoma at age 7. Both of the mutations described above were 
found in typical HNPCC families. The third published report of an MLH1-deficient child 
describes a girl homozygous for the deletion of exon 16 (Vilkki et al. 2001). The child died 
at the age of 4 of hemorrhage caused by a glioma, and had also clinical features of NF1. The 
fourth homozygous mutation, MLH1-R687W, was found in three children (Gallinger et al. 
2004). All the children showed features of NF1, and, remarkably, two children were 
diagnosed for gastrointestinal malignancies, one at the age of 9 years, and another at the age 
of 12 years. Furthermore, HNPCC-type malignancies were also found in other family 
members. 
 
The occurrence of a de novo NF1 syndrome in children homozygous for an MMR gene 
mutation suggests that the NF1 gene is a target for the mutator phenotype, and that NF1 
might be mutated at an early stage of embryogenesis. The mutations might be mosaic, 
affecting small fractions but not all cells (Tinschert et al. 2000). A specific feature of the NF1 
gene is its high rate of spontaneous mutations, which could be explained by the large size of 
the gene (approx. 350 kb), the excess of repetitive sequences, and gene conversions caused 
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by pseudogenes (Fahsold et al. 2000). A study with MLH1-deficient cell lines has revealed a 
high mutation rate in the NF1 gene as well (Wang et al. 2003).  
 
As discussed earlier, the alteration MLH1-P648S does not affect the functionality of the 
mutant MLH1, but does affect the protein stability. This was supported by the data obtained 
from our IHC analysis, which showed loss of MLH1 protein in the tumors of the family 
members. Finally, it is tempting to speculate that there might be a connection between the 
mild disease phenotype in the homozygote child and the pathogenicity of the mutation 
associated with shortage of the functional protein. The 6-year-old homozygous boy had only 
two small café-au-lait spots and one small skin tumor, and furthermore, he has not developed 
any hematological malignancies. However, more information about this homozygous patient 
is needed. For example, MSI analysis from different tissues would offer data about the 
degree and timing of the MMR defect.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 67
CONCLUSIONS AND FUTURE PROSPECTS 
 
 
The present study was undertaken to evaluate the pathogenicity of 34 minor MLH1 
alterations. Thirty-one of these were found in putative HNPCC families with varying clinical 
phenotypes and three were collected from the HNPCC mutation database. Using four 
different functional assays, we concluded that 24 were pathogenic mutations and 10 non-
pathogenic alterations.  
 
Twenty mutations affected the quantity of the MLH1 protein. Fourteen mostly aminoterminal 
mutations were defective in the in vitro MMR assay. Altogether, 22 mutations were 
pathogenic in more than one assay, two mutations were pathogenic only in one assay, and 10 
MLH1 variants acted similarly to the wild-type protein in the functional assays.  
 
Aminoterminal MLH1 mutations caused protein instability and repair deficiency most likely 
by affecting the ATP binding/hydrolysis capability of MLH1. Carboxylterminal mutations 
caused problems in protein stability and subcellular localization. Two carboxylterminal 
mutations affected the heterodimerization of MLH1 and PMS2 so severely that the protein 
variants were MMR deficient. Characterization of the biochemical defects facilitated the 
definition of functional domains of the MLH1 protein and revealed different mechanisms 
through which the pathogenic effects were mediated. 
 
By comparing the functional data and the clinical information obtained from the families we 
found that MLH1 variations with multiple, mild, or no defects in functional assays are linked 
to distinct clinical phenotypes. Our classification of the investigated variants as either 
pathogenic or non-pathogenic based on our in vitro results, was supported by the clinical 
associations. The MLH1 mutations which caused multiple defects in our functional assays 
were associated with the typical HNPCC phenotype, including early age of cancer onset and 
high MSI. In contrast, the MLH1 variants which acted like the wild-type protein were found 
in families with varying phenotypes including atypical or mild HNPCC characteristics. The 
results of the present study are hopefully useful to HNPCC diagnostics, counselling and 
design of appropriate follow-up strategies for mutation carriers in the respective families.  
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 It would be interesting to further characterize minor nontruncating MLH1 alterations, 
especially those, whose pathogenicity remains unclear in the present study. This could be 
done by  
– studying the effect of these variations on the assembly of MLH1-MLH3 and MLH1-PMS1 
heterodimers and the function of these heterodimers, especially of MLH1-MLH3, which is 
proposed to act in the repair of IDLs 
– studying the effect of these alterations on the interactions between MLH1 and other repair  
components such as MutS heterodimers, PCNA, and EXO1 
– studying the effect of these alterations on the mRNA level 
– studying the function of MLH1 in DNA damage signalling pathways in general 
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APPENDICES 
 
 
Table A.1. Experimental conditions for site-directed mutagenesis using pFastBac1-MLH1 
plasmid as a template. 
1st PCR   2nd PCR     
MLH
1 
variant 
 
Oligos for fragments A and B (5’→3’) 
Size 
(bp) 
T1
(°C
) 
Oligos 
(5’→3’
) 
Size 
(bp) 
T2
(°C
) 
 
Cloning 
sites 
MLH1-
P28L 
fA: CGCATTATTCATACCGTCCC 
rA: GATAGCATTAGCTAGCCGCTGGATAAC 
fB: GTTATCCAGCGGCTAGCTAATGCTATC 
rB: TTCTCCTCGTGGCTATGTTG 
178 
 
431 
45 
 
45 
fA 
rB 
571 45 BamHI 
PvuII 
MLH1-
A29S 
fA: fA-P28L 
rA: CTTTGATAGCATTAGATGGCCGCTGG 
fB: CCAGCGGCCATCTAATGCTATCAAAG 
rB: rB-P28L 
182 
 
426 
50 
 
50 
fA 
rB 
571 50 BamHI 
PvuII 
MLH1-
TSI45-
47CF 
fA: fA-P28L 
rA: CACTTGAAAACAGGATTTTGCATC 
fB: GATGCAAAATCCTGTTTTCAAGTG 
rB: rB-P28L 
229 
 
370 
50 
 
50 
fA 
rB 
568 45 BamHI 
PvuII 
MLH1-
D63E 
fA: fA-P28L  
rA: CCCGGTGCCATTTTCTTGGATCTG 
fB: CAGATCCAAGAAAATGGCACCGGG 
rB: rB-P28L 
283 
 
313 
50 
 
50 
fA 
rB 
571 50 BamHI 
PvuII 
MLH1-
G67R 
fA: fA-P28L  
rA: CTTCTTTCCTGATCCTGGTGCCATTGTC 
fB: GACAATGGCACCAGGATCAGGAAAGAAG 
rB: rB-P28L 
294 
 
304 
45 
 
45 
fA 
rB 
571 45 BamHI 
PvuII 
MLH1-
E71del 
fA: fA-P28L 
rA: CAATATCCAGATCTTTCCTGATCC 
fB: GGATCAGGAAAGATCTGGATATTG 
rB: rB-P28L 
308 
 
290 
60 
 
60 
fA 
rB 
568 60 BamHI 
PvuII 
MLH1-
C77R 
fA: fA-P28L  
rA: GTAGTGAACCTTTCACGTACAATATCCAG 
fB: CTGGATATTGTACGTGAAAGGTTCACTAC 
rB: rB-P28L 
327 
 
273 
45 
 
45 
fA 
rB 
571 45 BamHI 
PvuII 
MLH1-
F80V 
fA: fA-P28L 
rA: GTTTACTAGTAGTGACCCTTTCACATAC 
fB: GTATGTGAAAGGGTCACTACTAGTAAAC 
rB: rB-P28L 
336 
 
265 
45 
 
45 
fA 
rB 
571 45 BamHI 
PvuII 
MLH1-
K84E 
fA: fA-P28L 
rA: GGACTGCAGTTCACTAGTAGTGAAC 
fB: GTTCACTACTAGTGAACTGCAGTCC 
rB: rB-P28L 
343 
 
254 
45 
 
45 
fA 
rB 
571 45 BamHI 
PvuII 
MLH1-
S93G 
fA: fA-P28L 
rA: GCCATAGGTAGAAATACCGGCTAAATCCTC 
AAAGG 
fB: CCTTTGAGGATTTAGCCGGTATTTCTACC 
TATGGC 
rB: rB-P28L 
376 
 
230 
57 
 
57 
fA 
rB 
571 57 BamHI 
PvuII 
MLH1-
I107R 
fA: fA-P28L 
rA: GAGCCACATGGCTTCTGCTGGCCAAAGCC 
fB: GGCTTTGGCCAGCAGAAGCCATGTGGCTC 
rB: rB-P28L 
416 
 
184 
45 
 
45 
fA 
rB 
571 45 BamHI 
PvuII 
MLH1-
L155R 
fA: CTACCTATGGCTTTCG 
rA: CTATGTTGTAAAAACGGTCCTCCACCG 
fB: CGGTGGAGGACCGTTTTTACAACATAG 
rB: GGGGTTTGCTCAGAGGCTGC 
195 
 
759 
45 
 
45 
fA 
rB 
927 45 PvuII 
NsiI 
 82
MLH1-
V185G 
fA: fA-L155R 
rA: CTGCATTGTGTCCTGAATACCTGC 
fB: GCAGGTATTCAGGACACAATGCAG 
rB: rB-L155R 
281 
 
669 
50 
 
50 
fA 
rB 
927 45 PvuII 
NsiI 
MLH1-
V213M 
fA: fA-L155R  
rA: GCGAATATTGTCCATGGTTGAGGC 
fB: GCCTCAACCATGGACAATATTCGC 
rB: rB-L155R 
367 
 
583 
50 
 
50 
fA 
rB 
927 45 PvuII 
NsiI 
MLH1-
I219V  
fA: fA-L155R 
rA: CATTTCCAAAGACGGAGCGAATATTG 
fB: CAATATTCGCTCCGTCTTTGGAAATG 
rB: rB-L155R  
383 
 
569 
45 
 
45 
fA 
rB 
927 45 PvuII 
NsiI 
MLH1-
S247P 
fA: fA-L155R 
rA: GTAGTTTGCATTGGGTATGTAACCATTC 
fB: GAATGGTTACATACCCAATGCAAACTAC 
rB: rB-L155R 
470 
 
485 
45 
 
45 
fA 
rB 
927 45 PvuII 
NsiI 
MLH1-
H329P 
fA: fA-L155R  
rA: CTTGCTCTCGATGGGCTGCTGCACCCG 
fB: CGGGTGCAGCAGCCCATCGAGAGCAAG 
rB: rB-L155R 
716 
 
238 
45 
 
45 
fA 
rB 
927 45 PvuII 
NsiI 
MLH1-
I330del 
fA: fA-L155R 
rA: GGAGCTTGCTCTCGTGCTGCTGCAC 
fB: GTGCAGCAGCACGAGAGCAAGCTCC 
rB: rB-L155R 
719 
 
235 
45 
 
45 
fA 
rB 
924 45 PvuII 
NsiI 
MLH1-
K443Q 
fA: CGGGTGCAGCACATCG 
rA: GCTCTGATTTTGGGCAGCCACTTC 
fB: GAAGTGGCTGCCCAAAATCAGAGC 
rB: CTGATTATGATCCTCTAGTAC 
366 
 
1279 
45 
 
45 
fA 
rB 
1618 45 NsiI 
NotI 
MLH1-
L550P 
fA: fA-K443Q 
rA: CTTGGTGGTGTTGGGAAGGTATAACTTG 
fB: CAAGTTATACCTTCCCAACACCACCAAG 
rB: rB-K443Q 
690 
 
959 
45 
 
45 
fA 
rB 
1618 45 NsiI 
NotI 
MLH1-
A589D 
fA: fA-K443Q  
rA: CTGGACTATCTAAGTCAAGCATGGCAAG 
fB: CTTGCCATGCTTGACTTAGATAGTCCAG 
rB: rB-K443Q 
808 
 
841 
45 
 
45 
fA 
rB 
1618 45 NsiI 
NotI 
MLH1-
V612de
l 
fA: fA-K443Q 
rA: CTTCAGAAACTCAATGTATTCAGC 
fB: GCTGAATACATTGAGTTTCTGAAG 
rB: rB-K443Q 
876 
 
772 
60 
 
60 
fA 
rB 
1615 60 NsiI 
NotI 
MLH1-
K616de
l 
fA: fA-K443Q 
rA: GCAAGCATCTCAGCCTTCTTCAGAAACTC 
fB: GAGTTTCTGAAGAAGGCTGAGATGCTTGC 
rB: rB-K443Q 
893 
 
751 
45 
 
65 
fA 
rB 
1615 65 NsiI 
NotI 
MLH1-
K618A 
fA: fA-K443Q 
rA: 
GCAAGCATCTCAGCCGCCTTCTTCAGAAACTC 
fB: 
GAGTTTCTGAAGAAGGCGGCTGAGATGCTTGC 
rB: rB-K443Q 
896 
 
754 
45 
 
45 
fA 
rB 
1618 45 NsiI 
NotI 
MLH1-
K618T 
fA: fA-K443Q 
rA: 
GCAAGCATCTCAGCCGTCTTCTTCAGAAACTC 
fB: GAGTTTCTGAAGAAGACGCTGAGATGCTTGC 
rB: rB-K443Q 
896 
 
754 
45 
 
45 
fA 
rB 
1618 45 NsiI 
NotI 
MLH1-
Del633-
663 
fA: fA-K443Q 
rA: CGTCCCAATTCACCTCATCAATTTCC 
fB: GGAAATTGATGAGGTGAATTGGGACG 
rB: rB-K443Q 
937 
 
614 
45 
 
45 
fA 
rB 
1525 45 NsiI 
NotI 
MLH1-
Y646C 
fA: fA-K443Q 
rA: CCAAAGGGGGCACACAGTTGTCAATC 
fB: GATTGACAACTGTGTGCCCCCTTTGG 
rB: rB-K443Q 
979 
 
669 
45 
 
45 
fA 
rB 
1618 45 NsiI 
NotI 
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MLH1-
P648L 
fA: fA-K443Q 
rA: GTCCCTCCAAAGGGAGCACATAGTTGTC 
fB: GACAACTATGTGCTCCCTTTGGAGGGAC 
rB: rB-K443Q 
985 
 
664 
45 
 
45 
fA 
rB 
1618 45 NsiI 
NotI 
MLH1-
P648S 
fA: fA-K443Q 
rA: CCAAAGGGGACACATAGTTGTC 
fB: GACAACTATGTGTCCCCTTTGG 
rB: rB-K443Q 
985 
 
664 
45 
 
45 
fA 
rB 
1618 45 NsiI 
NotI 
MLH1-
P654L 
fA: fA-K443Q 
rA: GAATGAAGATAAGCAGTCCCTCCAAAGG 
fB: CCTTTGGAGGGACTGCTTATCTTCATTC 
rB: rB-K443Q 
1000 
 
648 
45 
 
45 
fA 
rB 
1618 45 NsiI 
NotI 
MLH1-
R659P 
fA: fA-K443Q 
rA: 
CCTCAGTGGCTAGTGGAAGAATGAAGATAGGC 
fB: GCCTATCTTCATTCTTCCACTAGCCACTGAGG 
rB: rB-K443Q 
1018 
 
632 
45 
 
45 
fA 
rB 
1618 60 NsiI 
NotI 
MLH1-
R659Q 
fA: fA-K443Q  
rA: CAGTGGCTAGTTGAAGAATGAAGATAG 
fB: CTATCTTCATTCTTCAACTAGCCACTG 
rB: rB-K443Q 
1015 
 
634 
60 
 
60 
fA 
rB 
1618 60 NsiI 
NotI 
MLH1-
A681T 
fA: fA-K443Q 
rA: GAATAGAACATAGTGCATTCTTTAC 
fB: GTAAAGAATGCACTATGTTCTATTC 
rB: rB-K443Q 
1082 
 
564 
60 
 
60 
fA 
rB 
1618 60 NsiI 
NotI 
MLH1-
V716M 
fA: fA-K443Q 
rA: GACAATGTGTTCCATAGTCCACTTCCAG 
fB: CTGGAAGTGGACTATGGAACACATTGTC 
rB: rB-K443Q 
1188 
 
461 
45 
 
45 
fA 
rB 
1618 45 NsiI 
NotI 
1 annealing temperature in 1st PCR; 2 annealing temperature in 2nd PCR 
 
 
Table A.2. Characteristics of different plasmids used in the present study.  
 
Plasmid 
 
Purpose of use 
 
Reference 
 
Insert 
Cloning sites 
of insert 
Selection 
in E.coli 
Original 
plasmid 
pFast-Bac1-
MLH1 
Generation of 
baculoviruses for 
protein expression in 
Sf9 cells 
Prof. Josef 
Jiricny, 
University of 
Zürich 
MLH1 BamHI + NotI ampicillin pFastBac1 
(Invitrogen)
pFast-Bac1-
PMS2 
Generation of 
baculoviruses for 
protein expression in 
Sf9 cells 
Prof. Josef 
Jiricny, 
University of 
Zürich 
PMS2 BamHI + XbaI ampicillin pFastBac1 
(Invitrogen)
pEGFP-N1 Protein expression in 
293T 
human cells 
Clontech EGFP BamHI + NotI kanamycin .. 
pMLH1-N1 Protein expression in 
293T 
human cells 
Present study MLH1 BamHI + NotI kanamycin pEGFP-N1 
(Clontech) 
pPMS2-N1 Protein expression in 
293T 
human cells 
Present study PMS2 BamHI + NotI kanamycin pEGFP-N1 
(Clontech) 
pMLH1-EGFP Protein expression in 
293T 
human cells 
Present study MLH1-
EGFP fusion 
gene 
NheI + SacI 
(MLH1) 
kanamycin pEGFP-N1 
(Clontech) 
pPMS2-EGFP Protein expression in 
293T 
human cells 
Present study PMS2-EGFP
fusion gene
BamHI + AgeI
(PMS2) 
kanamycin pEGFP-N1 
(Clontech) 
pGEM Preparation of DNA 
heteroduplex 
Promega .. .. ampicillin .. 
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Table A.3. Cell lines used in the present study.  
Cell 
line 
 
Specification 
 
Special characters 
 
Reference 
Used in original 
publication 
Sf9  insect (Spodoptera frugiperda 
9) ovarian cells 
.. Invitrogen I-IV 
293T  human embryonic kidney cells loss of MLH1 protein Trojan et al. 2001 II-IV 
TK6  human lymphoblastoid cells .. ATCC I-IV 
HCT116  human colon carcinoma cells loss of MLH1 protein ATCC I-IV 
ATCC, American Type Culture Collection. 
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